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Tetraploidy and chromosomal instability are common phenotypes of malignant cells and 
cytokinesis failure is a known source of tetraploidy. However, the causes of cytokinesis failure 
are not yet identified. An essential step in the process of cytokinesis is phosphorylation of 
myosin regulatory light chain (MLC), required for actin–myosin interaction and the formation of 
the cleavage furrow. Our data indicate that cancer cells are deficient in MLC phosphorylation 
and this deficiency is the cause of cytokinesis failure. Myosin light chain kinase (MLCK) is a 
key enzyme that phosphorylates MLC during cytokinesis and is inhibited in cancer cells. Aurora 
B kinase is an essential regulator of cytokinesis that is commonly over-expressed in cancer cells 
and can phosphorylate MLCK in vitro. Therefore we hypothesize that Aurora B over-expression 
is the cause of MLCK inhibition in cancer cells. Consistent with our hypothesis, we demonstrate 
that Aurora B kinase indeed is an MLCK inhibitor in vitro and in cultured mammalian cells. 
Cytokinesis failure resulting from Aurora B over-expression can largely be suppressed by 
constitutively active MLCK or phosphomimetic MLC and reducing protein levels of Aurora B in 
cancer cells increases MLCK activity and decreases cytokinesis failure. These data thus describe 
a novel pathway that drives Aurora B induced cytokinesis failure.  
Cytokinesis failure is often observed in only a subset of cancer cells but the trigger for 
this divisional failure in that subset is unknown. One strong possibility is the presence of 
lingering chromatin at the cleavage site that has been previously proposed to block cytokinesis 
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completion. However, the mechanism linking lingering chromatin and cytokinesis failure is still 
a mystery. In this study we demonstrate that lingering chromatin causes cytokinesis failure by 
inducing over-expression of Aurora B and the resultant inhibition of MLCK and phosphorylated 
MLC. Together, my results define a novel pathway for Aurora B mediated regulation of 
cytokinesis and contribute to our understanding of the genomic destabilizing events of 
tumorigenesis.  
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1.0  INTRODUCTION 
Every time a cell divides, it separates its duplicated genome equally amongst the two daughter 
cells. Aberrant cell division can result in unequal distribution of the genome, forming daughter 
cells with a deviation from the diploid number of chromosomes and any changes in the ploidy of 
the cells can have serious consequences such as development of cancer. Cancer has been 
interpreted as a complex Darwinian adaptive system that slowly evolves through natural 
selection of cellular clones (Greaves and Maley, 2012). The classical ‘clonal evolution’ model of 
cancer suggests that a tumor evolves by stepwise accumulation of somatic mutations and clonal 
expansion of the selective mutations (Nowell, 1976). This model describes that a progenitor cell 
that has acquired mutations provides selective growth advantages and initiates cancer. The 
resultant neoplastic clones expand either immediately or after a prolonged latent period. Genetic 
instability in the tumor population gives rise to additional clones with even more favorable 
mutations that expand further. The tumor thus evolves gradually over a prolonged period of time 
ranging over many years. A recent evidence for the presence of large-scale punctuated changes 
in cancer cells, driven by sudden catastrophic mitotic events that results in multiple genomic 
rearrangements, have argued that ‘punctuated equilibrium’ can also contribute to cancer 
evolution along with gradualism (Stephens et al., 2011). Changes in the ploidy of the cells, 
specifically whole genome duplication, has played an important role during speciation (Semon 
and Wolfe, 2007). A recent high throughput analysis of cancer genomes indicates that genome 
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doubling events occur commonly during the evolution of caner genome as well (Carter et al., 
2012). Change in the ploidy of a cell can be a source for both these mutational changes, ones that 
are acquired gradually over a prolonged period of time or the ones that are acquired in a shorter 
time frame via sudden punctuated changes, over the course of cancer evolution. Therefore, 
understanding the causes and consequences of changes in ploidy is an active and important area 
of cancer research.  
1.1 TETRAPLOIDY  
Polyploidy refers to a state of having greater than diploid (2N) number of chromosomes. 
Tetraploidy is a polyploid condition characterized by double (4N) the normal complement of 
chromosomes. Polyploid cells are frequently observed in plants (Galbraith et al., 1991). 
Surprisingly, even in mammals, occurrence of physiologically normal polyploidy, most 
commonly tetraploidy, is not a rare phenomenon. Megakaryocytes, the precursors of platelets, or 
cells of the mammalian placenta called trophoblasts, become polyploid as a part of their 
developmental program (Ravid et al., 2002; Zybina and Zybina, 2005). In adult rats, around 70% 
of hepatocytes are tetraploid, whereas in humans around 20-30 % of hepatocytes are polyploidy 
or tetraploid when they terminally differentiate (Guidotti et al., 2003). Other than liver, polyploid 
cells are also observed in many other tissues such as brain, urothelium, mesothelium, normal and 
lactating breast, to name a few. The presence of polyploid cells in such a variety of tissues under 
normal conditions has thought to be a part of differentiation or functional adaptation (Biesterfeld 
et al., 1994).  
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                  Polyploidy can be advantageous under certain circumstances. For example, 
polyploidy has played an important role during the evolution of eukaryotes (Otto, 2007). 
Tetraploidy is also observed during some types of cellular stress responses. For example, liver 
cells or hepatocytes regenerated after exposure to toxic drugs or after partial hepatectomy are 
predominantly polyploid (Fausto and Campbell, 2003).  Heart muscle and vascular smooth 
muscle cells that are diploid under normal conditions become polyploidy during hypertension. 
Polyploid fibroblast have also been observed during wound healing and finally polyploidy is 
often correlated with senescence and aging (Storchova and Pellman, 2004).  The presence of 
tetraploids during a cellular stress response can be advantageous as it can help tissues to switch 
to an energy saving mode by regulating organ size and increasing the production of ATP to 
confer metabolic benefits (Anatskaya and Vinogradov, 2010). Polyploidy can also protect 
against genotoxic stress by increasing the gene copy number allowing enhanced expression of 
key genes important for the stress response (Storchova and Pellman, 2004). This can be 
specifically important for tissues such as liver that primarily function in metabolizing toxic 
products.  
1.1.1 Tetraploidy induced tumorigenesis  
Although polyploidy can be advantageous under certain circumstances, unscheduled polyploidy 
comes with a cost. Germline polyploidy is often lethal and accounts for 5 to 10% of spontaneous 
abortions (Vitale et al., 2010).  Perhaps one of the major disadvantages of somatic polyploidy or 
tetraploidy from a human health perspective is that it acts as a trigger for cell transformation and 
tumorigenesis (Ganem et al., 2007; Storchova and Kuffer, 2008; Storchova and Pellman, 2004; 
Vitale et al., 2010). Several lines of evidence suggest that tetraploids are transient intermediates 
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during tumorigenesis. In a variety of rodent cell lines cultured in vitro, development of 
tetraploidy or hypertetraploidy has been observed to accompany spontaneous neoplastic 
transformation (Shackney et al., 1989). Tetraploid cells have been observed in early stages of 
diverse tumor types. In a premalignant esophageal cancer, called Barrett’s esophagus, occurrence 
of tetraploid cells precedes appearance of aneuploid tumors and correlates with the mutational 
inactivation of the p53 tumor suppressor gene (Galipeau et al., 1996). Tetraploids are often 
observed during early stages of cervical cancer and they predispose such cells to aneuploid 
cancer formation, frequently involving loss of chromosome 17 (Olaharski et al., 2006). Early 
stages of malignant gliomas, colonic adenocarcinomas and advanced stages of bladder cancers 
are other examples of tumors with tetraploid cell populations (Jakobsen et al., 1983; Park et al., 
1995; Takanishi et al., 1996). 
              While these descriptive studies suggest a role for ploidy changes in cancer, they are only 
a correlation and many other cellular changes accompany transformation. However more 
recently direct experimental studies in animal models have shown that tetraploidy is sufficient 
for tumor formation in mice. p53-/- mouse mammary epithelial cells made tetraploid after 
treatment with the actin inhibitor dihydrocytochalasin B (DTB) form tumors roughly 25% of the 
time upon subcutaneous injection into nude mice. However, diploid cells injected using the same 
procedure do not form tumors (Fujiwara et al., 2005). This seminal work shows that tetraploidy 
of an otherwise normal genome is sufficient to form tumor in the mouse xenograft model.  
To follow up on this observation, similar studies using mechanisms of tetraploidy that 
may be relevant to cancer confirmed this conclusion. For example, injection of sorted tetraploid 
cells formed as a result of over-expression of a downstream target of c-Myc, called as Gp1bα, 
commonly over-expressed in cancer cells, also form larger, faster and more aggressive tumors 
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upon injection into nude mice, as compared to smaller and slower growing tumors formed upon 
injection of diploid cells over-expressing Gp1bα (Li et al., 2008). Thus the selection of 
tetraploids among identical cells enhances tumorigenesis in mice. In both of these examples, the 
cancer cells isolated after tumor formation are aneuploid and genetically unstable, similar to 
human tumor cells. These experimental observations strongly demonstrate causality between 
tetraploidy and tumorigenesis. Thus, both the correlative studies in human patients and the 
experimental evidence support the hypothesis that tetraploid cells act at an early stage leading to 
formation of aneuploid and genetically unstable tumors.  
 
1.1.2 Mechanism of tetraploidy induced tumorigenesis  
One of the major changes that accompany polyploidy is loss of genetic stability. Tetraploid cells 
demonstrate scaling effects, i.e. they have double the content of DNA and double the number of 
centrosomes, as compared to diploid cells. Two major consequences of this scaling effect that are 
proposed to contribute towards tetraploidy induced tumorigenesis are (a) generation of aneuploid 
progeny as a result of increased frequency of chromosome mis-segregation and (b) increased 
frequency of DNA damage. Both outcomes are inter-related. 
1.1.3 Generation of aneuploid progeny from tetraploid cells and their role in tumor 
development 
One of the most striking features of tetraploidy induced tumors is the formation of aneuploid and 
chromosomally unstable tumor cells (Fujiwara et al., 2005; Li et al., 2008). Chromosomal 
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instability (CIN) is defined as persistently high rates of gain or loss of whole or a fraction of a 
chromosome during cell division. An abnormal numbers of chromosomes, either more or less 
than the diploid number, is defined as aneuploidy (Geigl et al., 2008; Gordon et al., 2012). 
Whole chromosome aneuploidy refers to the changes in the number of whole chromosome and 
segmental aneuploidy refers to the chromosomal rearrangement like deletion, amplifications or 
translocations (Geigl et al., 2008). Both of these changes are present in cancer cells obtained 
from tetraploid induced tumors and appear to be a consequence of tetraploidy in these cells.  
CIN and aneuploidy is perhaps the most distinguishing genomic characteristic of most of 
the solid tumors as well as leukemias and lymphomas (Thompson and Compton, 2011). 
According to the Mitelman Database, a large repository of cytological data from over 60,000 
human cancer cases, aneuploidy is observed in a majority of cancers. A typical solid tumor 
karyotype can range from 40 to 60 chromosomes, sometimes even exceeding 70 (Mitelman et 
al., 2012). A recent comprehensive study using high-resolution mapping of somatic copy number 
alterations (SCNA) in cancer cells has revealed that 25% of the cancer cell genome is affected by 
whole chromosome or chromosome arm level SCNA and 10% is affected by focal SCNA 
(Beroukhim et al., 2010). CIN is also present in the majority of the tumor cells (Lengauer et al., 
1997; Thompson and Compton, 2011). Moreover, CIN and aneuploidy are interdependent and 
aneuploidy often arises as a result of underlying CIN (Holland and Cleveland, 2009). 
Conversely, aneuploidy can also drive genomic instability under certain circumstances (Sheltzer 
et al., 2011). In spite of the presence of a widespread aneuploidy, its precise role in 
tumorigenesis is still under investigation. 
More than a century ago, a German scientist Theodor Boveri proposed that aneuploidy is 
the cause of cancer (Boveri, 1914; Manchester, 1995). Boveri observed that sea urchin embryos 
 7 
developed from multipolar divisions form cancerous growths. Based on these data and the 
observations of German pathologist David Hansemann of asymmetrical anaphases and 
telophases in epithelial tumors, Boveri proposed that tumors arise from a progenitor cell that 
possesses an incorrectly combined set of chromosomes (known in today’s world as aneuploidy).  
Since the time of Boveri, contribution of aneuploidy to tumorigenesis has been strongly 
debated. As four to six successive mutations are required for cancer formation (Kinzler and 
Vogelstein, 1996), skeptics of the aneuploidy hypothesis have argued that aneuploidy is merely a 
benign side effect of the process of transformation and does not play a role in driving tumor 
development (Zimonjic et al., 2001).  
However, many yeast and mice models have provided ample of evidence for fitness 
benefits of aneuploidy and its causative role in tumor development. Comparison of 38 aneuploid 
yeast strains with their euploid counterparts demonstrates that many aneuploid strains grow 
significantly better under various stress conditions and drug exposure and do not acquire 
additional mutations (Pavelka et al., 2011). Thus, it appears that aneuploidy itself provides the 
enhanced growth potential and is not just a way of acquiring additional mutations. Aneuploid 
mouse models developed from altered expression of spindle assembly checkpoint proteins such 
as Mad1, Mad2 and Bub1 develop a variety of tumors ranging from benign lung tumors to lethal 
lymphomas, lung, liver and spleen cancers and some are prone to develop carcinogen induced 
tumors (Baker et al., 2009; Holland and Cleveland, 2009; Iwanaga et al., 2007; Michel et al., 
2001).   
Aneuploidy is observed in many premalignant conditions in humans and precedes the 
process of transformation (Weaver and Cleveland, 2006). The presence of aneuploidy positively 
correlates with more aggressive tumors and worse prognosis in the general population (Shackney 
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et al., 1989). Moreover, aneuploidy generated by CIN is responsible for tumor relapse and 
recurrence (Sotillo et al., 2010). A recessive genetic condition known as mosaic variegated 
aneuploidy (MVA) is characterized by mosaic aneuploidy involving different chromosomes and 
tissues (Tolmie et al., 1988). Children suffering from this condition develop cancer at higher 
frequencies (Jacquemont et al., 2002; Kajii et al., 2001). Patients of Down’s syndrome, 
characterized by trisomy 21, have significantly increases risk of hematological malignancies 
(Hitzler and Zipursky, 2005). All these data provide a strong line of evidence supporting the 
causal role of aneuploidy in tumorigenesis.  
However, aneuploidy does not always result in tumor development. In many instances 
aneuploidy is not compatible with whole organism viability. Children born with trisomy 13 or 18 
do not survive beyond few days of life (Rasmussen et al., 2003).  Mouse embryonic cell lines 
engineered to be trisomic for specific chromosomes display embryonic lethality (Williams et al., 
2008). Surprisingly, aneuploidy also acts as a tumor suppressor under certain conditions and in 
certain tissues (Weaver et al., 2007).  
Whole chromosome or segmental aneuploidy involves altered expression of multiple 
different genes and pathways, depending upon the chromosomes involved. Therefore, these 
paradoxical roles of aneuploidy as a tumor inducer and tumor suppressor can be explained by the 
differences in the chromosomes involved and the differences in the extra-cellular environment 
that different aneuploid cells are exposed to. Thus, although aneuploidy can be fatal in certain 
circumstances, it might improve fitness and provide survival benefits under specific conditions. 
Tetraploid cells have an additional set of the entire genome that can be specifically advantageous 
for the survival of aneuploid progeny as the additional chromosomes can buffer the effect of gain 
or loss of chromosomes that would otherwise be detrimental in the diploid genome. Consistent 
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with this hypothesis, tetraploid cells with CIN show near normal growth rates compared to 
isogenic diploid strains and can tolerate nearly 1000 fold increase in the rate of gain or loss of 
chromosome without major impairment of cell cycle progression (Ganem et al., 2009; Storchova 
et al., 2006).   
Although outcomes of aneuploidy can differ under different circumstances, all aneuploid 
cells show similar signs of energy and proteotoxic stress (Tang et al., 2011). These common 
downstream effects of aneuploidy are attractive targets for developing new anti-cancer therapies. 
Therefore, continued efforts are warranted for the study of the causes and consequences of 
aneuploidy for the better understanding of the process of tumorigenesis and also for the 
development of new therapeutic strategies.  
1.1.3.1 Chromosome segregation defects as an underlying cause of aneuploid progeny  
 
Recent work performed using diploid and tetraploid yeast cells have demonstrated that certain 
alleles are required for the survival of polyploid (tetraploid) cells but not for the survival of 
diploid cells. This phenomenon is referred to as ploidy specific lethality (PSL) (Lin et al., 2001; 
Storchova et al., 2006). Interestingly all of the PLS gene products are required for maintaining 
genomic stability such as the genes required for proper chromosome segregation, sister 
chromatid cohesion or homologous recombination (Lin et al., 2001; Storchova et al., 2006). 
Consistent with this analysis, chromosome segregation errors occur at significantly higher rates 
in tetraploid cells and appear to be the primary cause of tetraploidy induced aneuploidy.  
Tetraploid cells demonstrate chromosome segregation errors because of the higher 
frequencies of incorrect kinetochore-microtubule attachments such as merotely and syntely. 
Merotely is a condition characterized by the attachment of a single sister chromatid to both the 
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spindle poles whereas syntely is defined as the attachment of both sister chromatids to one 
spindle pole (Kapoor, 2004).  
Tetraploidy leads to the doubling of the centrosome number as well as doubling of the 
genome. In mitosis, each centrosome is located at the poles of a bipolar mitotic spindle. 
Therefore, the presence of more than two centrosomes can result in the formation of multipolar 
spindles, as was observed by Boveri. Formation of multipolar spindles can then lead to an 
unequal distribution of chromosomes and aneuploidy. However, the progeny of multipolar 
divisions are frequently inviable in vitro (Ganem et al., 2009) and the cytoplasmic motor dynein 
can cluster extra centrosomes into two poles (Quintyne et al., 2005). Interestingly, it was recently 
demonstrated that cells with extra centrosomes often undergo bipolar division and only 
transiently pass through a multipolar stage (Ganem et al., 2009). But, the presence of this 
transient multipolar stage leads to an increased incidence of merotelic kinetochore-microtubule 
attachments. Segregation of merotelically attached chromosomes can lead to a tug-of-war 
between the microtubules emanating from the opposite spindle poles and can cause 
chromosomes to lag behind and mis-segregate giving rise to aneuploid daughter cells. 
Consistently, an increase in the centrosome numbers or centrosome amplification and formation 
of multipolar spindles is frequently observed in cancers (Nigg, 2006; Saunders et al., 2000) and 
is positively correlated with genomic instability and cancer progression (Pihan et al., 2001; Sato 
et al., 2001). 
Another source of defective chromosome segregation often observed in tetraploid cells is 
syntelic kinetochore-microtubule attachment. In tetraploid cells, the cell volume increases with 
the genome size but the size of pre-anaphase spindle does not increase and the spindle geometry 
is altered (Storchova et al., 2006). This disparity in the scaling of the genome versus spindle size 
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leads to an increased incidence of syntelically-attached chromatids that can also lag behind and 
mis-segregate. In summary, tetraploid cells produce aneuploid progeny because they mis-
segregate chromosomes and the resultant aneuploid progeny acts as the progenitor of tetraploidy 
induced tumors.  
1.1.4 Increased DNA damage associated with tetraploidy and aneuploidy 
Another consequence of tetraploidy generation is an increase in the DNA damage. Although the 
kinetics of DNA replication are unaltered in tetraploid cells, they accumulate twice the DNA 
damage during S-phase, probably as a consequence of genome doubling (Storchova et al., 2006). 
Primary tetraploid human fibroblasts display an increase in γ-H2X foci compared to their diploid 
counterparts, a marker for DNA damage, (Hau et al., 2006). Tetraploid yeast also shows 
increased sensitivity to γ-radiation and other DNA damaging agents (Mayer et al., 1992; 
Mortimer, 1958).  
1.1.4.1 Chromosome segregation errors as a source of DNA damage 
 
Chromosome segregation errors also act as a source of DNA damage in tetraploid cells. Mis-
segregating chromosomes often lag behind other chromosomes during anaphase and become 
damaged if cytokinesis proceeds in the presence of uncleared chromatin at the cleavage plane. 
The damaged DNA then elicits DNA double strand break repair and unbalanced translocations 
leading to aneuploidy (Janssen et al., 2011).  
             Mis-segregating chromosomes such as lagging chromosomes often form micronuclei 
adjacent to the parent nucleus. Chromosomes present in the micronuclei undergo asynchronous 
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and defective DNA replication. If cells enter mitosis while micronuclear DNA is still undergoing 
replication, chromosome pulverization can occur causing extensive DNA damage and 
fragmentation of chromosomes that can integrate back into the genome (Crasta et al., 2012). 
Pulverization of micronuclear DNA can be a source of a recently reported DNA damaging 
phenomenon of cancer cells termed as ‘chromothripsis’, whereby hundreds of genomic 
rearrangements occur during a single catastrophic event. In contrast to a serial accumulation of 
tumorigenic mutations over a long period of time, events like chromothripsis lead to massive 
tumorigenic mutational changes in a very short period of time (Stephens et al., 2011).   
                 Long term imaging of tetraploid cells in real time indicate that the majority of 
tetraploid cells do not survive beyond four to five cell divisions, independent of their p53 status 
(Krzywicka-Racka and Sluder, 2011). Such a short survival of tetraploid cells seriously questions 
their tumorigenic potential. However, as tetraploid cells frequently mis-segregate chromosomes, 
they appear to be more prone to undergo sudden mutational changes such as chromothripsis. If 
this is true, even a life span of a few cell cycles may be sufficient to accumulate tumorigenic 
genomic changes.  
Gene expression imbalances associated with aneuploidy can further increase the rate of 
spontaneous DNA damage by altering the cellular processes that usually cause or repair normally 
lower levels of DNA damage. Additionally, the extra set of chromosomes present in tetraploid 
cells may buffer the effect of deleterious mutations by providing an extra copy of normal allele. 
This masking effect might allow cells with DNA damage to survive longer until they accumulate 
an optimized mutational load. This is demonstrated using a haploid and a diploid yeast strain in a 
long-term evolution experiments where diploid yeast with defective mismatch repair show 
significant survival advantage over haploid yeast (Thompson et al., 2006). In summary, 
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tetraploid cells play a causal role in tumorigenesis by increasing the DNA damage and producing 
aneuploid progeny.  
1.1.5 Tetraploidy checkpoints  
Considering all the deleterious effects caused by tetraploidy, it is not surprising that cells have 
evolved checkpoint mechanisms to eliminate tetraploid cells. Non-transformed rat fibroblasts 
made tetraploid with a cytokinesis inhibitor DCB, arrest in G1 stage of cell cycle in a p53 
dependent manner (Andreassen et al., 2001). In contrast, DCB treated cells can proliferate upon 
transfection with the SV-40 virus that inactivates p53 (Wright and Hayflick, 1972). Tetraploid 
cells formed by virus induced cell - cell fusion can propagate in the culture only in the absence of 
p53 (Duelli et al., 2005). All these data suggest the existence of a ‘tetraploidy checkpoint’ 
mediated by p53 that blocks the proliferation of tetraploid cells. However, the mechanism of p53 
activation in tetraploid cells is unclear. 
Tetraploid cells can also be eliminated by p53 driven apoptosis. Inhibition of apoptosis in 
a variety of cell types leads to increased prevalence of tetraploid populations (Nelson et al., 
2004). Tetraploid cells can activate a Bax-dependent apoptosis and depletion of Bax enhances 
survival of tetraploid cells (Castedo et al., 2010). Therefore, it is likely that mutations in p53, as 
frequently observed in a variety of tumor types, are important for the survival of tetraploid cells 
during tumorigenesis.  
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1.1.6 Origins of tetraploid cells  
Given the role of tetraploid cells in tumor development, is it crucial to understand the causes of 
tetraploid cell formation in order to understand the disease better and also to develop therapies 
that may target tetraploids or interfere with the process of tetraploidization. The following are the 
mechanisms that can hypothetically result in the formation of tetraploid cells.  
1.1.6.1 Cell-cell fusion  
Myocytes and osteoclasts undergo cell-cell fusion as a part of their normal developmental 
program (Storchova and Pellman, 2004). Cell-cell fusion also happens spontaneously in cell 
culture (Duelli et al., 2005) or following infection with certain viruses and the resultant 
tetraploidy may enhance transformation and tumorigenesis (Duelli et al., 2005).  
1.1.6.2 Endoreplication  
Endoreplication is defined as a phenomenon in which cells undergo repeated rounds of 
DNA replication without undergoing mitosis. Cells undergoing endoreplication thus become 
polyploidy by uncoupling DNA replication with mitosis. Endoreplication is most commonly 
observed during normal developmental processes. Cells of Drosophila salivary glands can 
completely skip mitosis and become polyploidy via endoreplication (Edgar and Orr-Weaver, 
2001). Human megakaryocytes, and placental trophoblasts are common examples of cells that 
become polyploid by endoreplication (Ravid et al., 2002; Zybina and Zybina, 2005). Cells that 
undergo endoreplication do not typically have amplified centrosomes and would not have the 
mitotic defects and chromosomal instability associated with extra centrosomes in the cell. 
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1.1.6.3 Mitotic slippage 
Prolonged arrest of cells in mitosis can result in premature exit from mitosis and reentry 
into G1 without completion of chromosome segregation and cytokinesis, a phenomenon termed 
as mitotic slippage. Mitotic slippage is frequently observed in cells treated with microtubule 
inhibitors or other conditions that cause incorrect kinetochore-microtubule attachment activating 
spindle assembly checkpoint (SAC) and delay in mitosis for a prolonged period of time (Rieder 
and Maiato, 2004; Xu et al., 2010). 
1.1.6.4 Cytokinesis failure 
Cells that replicate DNA and enter mitosis but fail to complete cytokinesis become 
tetraploid. Cytokinesis failure is usually observed in pathological conditions. For example, liver 
cells become tetraploid under stress, predominantly by incomplete cytokinesis (Guidotti et al., 
2003).  
Most importantly, cancer cells appear to become tetraploid by failure of cytokinesis 
(Steigemann et al., 2009; Wu et al., 2010a). 
Cytokinesis failure and cancer  
Live cell-imaging analysis of cancer cells done in our laboratory has demonstrated that 
approximately 10% of cancer cells fail at cytokinesis depending upon the cancer cell type. These 
cells begin to ingress the cleavage furrow but later it regresses back and binucleated, tetraploid 
cells are formed. Cell-cell fusion is rarely observed in the tested cancer cell populations (Wu et 
al., 2010a). Furthermore, all cells with multipolar spindles fail cytokinesis in the previous 
division. Thus, cytokinesis failure appears to be the primary source of tetraploidy and 
multipolarity in cancer cells. As demonstrated in (Figure 1), tetraploid cells formed as a result of 
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cytokinesis failure pass through a pseudobipolar mitotic stage because of the presence of an extra 
set of chromosomes and extra centrosomes. This leads to chromosome segregation errors 
resulting in the formation of aneuploid progeny that can promote tumorigenesis. 
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Figure 1. Role of cytokinesis failure in tumorigenesis. 
 (A) Normal cell division produces two diploid daughter cells with a single centrosome (B) Cells that 
fail in cytokinesis produce a single tetraploid cell with double the number of chromosomes and centrosomes. 
As a result of this doubling, subsequent divisions of tetraploid cells occur with an increased frequency of 
chromosome segregation errors and DNA damage. The resultant aneuploid progeny can then stimulate 
tumorigenesis.  
 
Many known regulators of cytokinesis are mis-regulated in cancer cells and can 
contribute to tetraploidy (Sagona and Stenmark, 2010). Cells over-expressing oncogene Gp1bα 
become tetraploid as a result of cytokinesis failure (Wu et al., 2010b). Loss of Aurora B kinase 
can also trigger regression of the cleavage furrow (Steigemann et al., 2009). But the mechanisms 
leading to tetraploidy in cancer cells are just beginning to be investigated. Given the disastrous 
consequences of cytokinesis failure, it is necessary to understand its origins. This is the primary 
goal of this dissertation. In order to discuss cytokinesis failure, it is first important to clarify the 
normal process of cytokinesis.     
1.2 CYTOKINESIS AND ITS REGULATION 
 Cytokinesis is the final step of mitosis when the cytoplasm is divided into two daughter cells. It 
is a remarkably complicated process and needs coordinated action and regulation of more than 
100 proteins (Pollard, 2010). Although the goal of cytokinesis is conserved in all the organisms 
i.e. to separate a mother cell into two daughter cells, different organisms carry out cytokinesis a 
little differently. Metazoans primarily divide by the formation of an actin-myosin contractile 
ring, whereas plant cells divide by building a cell plate between the two dividing daughter cells.  
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As the goal of this dissertation is to understand cytokinesis failure in human cancer cells, the 
following section will primarily discuss the mechanism of cytokinesis in animal cells.  
The process of cytokinesis can be divided into four different stages as follows, 
specification of the cleavage plane, formation and ingression of an actin-myosin contractile ring, 
midbody formation and abscission (Normand and King) (Figure 2). 
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Figure 2. Stages of cytokinesis.  
Process of animal cell cytokinesis can be divided into four different steps. Step-1 determines the site 
of division plane. Step-2 occurs with the formation and ingression of an actin-myosin based contractile ring. 
Step-3 results in the formation of the midbody and Step-4, known as abscission, is responsible for a physical 
separation of the dividing cell into two daughter cells.  
 
1.2.1 Step 1-Specification of the division site 
Accurate spatial and temporal regulation of cytokinesis depends upon positioning of the cleavage 
site between the segregating chromosomes, only after chromosomes have sufficiently separated. 
Furthermore, the divisional plane must be near the center of the cell, to allow equal partitioning 
of the cytoplasm, or positionally biased in the case of asymmetrical division. Therefore, the cell 
uses multiple cues to achieve correct positioning of the cleavage furrow. Classical experiments 
performed using sand dollar eggs demonstrate that if the mitotic spindle is displaced by physical 
manipulation, the existing cleavage furrow regresses and a new one forms at the site of the new 
spindle midplane (Rappaport, 1997). These and many other studies establish a central role of the 
mitotic spindle apparatus in providing spatial cues for positioning of the cleavage furrow. 
Specifically two components of the mitotic spindle, spindle asters and the spindle midzone, are 
most important for positioning the division site (Bringmann and Hyman, 2005). Spindle asters 
consist of radial arrays of microtubules nucleated by the centrosomes. Astral microtubules that 
grow towards the cell pole are called polar astral microtubules and astral microtubules that reach 
up to the equatorial region of the cell are called equatorial astral microtubules (Burgess and 
Chang, 2005). The polar relaxation and equatorial stimulation model of furrow positioning 
suggests that polar astral microtubules relay signals that inhibit contractility at the polar cortex 
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whereas, equatorial astral microtubules deliver positive signals that stimulate the formation and 
the contractility of the cleavage furrow at the equatorial cortex (Burgess and Chang, 2005).  
Another component of the mitotic spindle that provides spatial cues for the site of 
cytokinesis is the spindle midzone. The spindle midzone or central spindle consists of bundles of 
antiparallel, non-kinetochore microtubules situated between the two spindle poles during 
cytokinesis and the proteins associated with these microtubules. As cytokinesis proceeds, the 
central spindle becomes compacted into a structure called the midbody. A heterotetrameric 
centralspindlin complex is necessary for the bundling of anti-parallel microtubules in the central 
spindle. This complex consists of the kinesin-6 motor protein MKLP-1 and an activator of Rho 
GTPase activity called RhoGAP CYK-4 (Mishima et al., 2002). The centralspindlin complex, 
specifically CYK-4, recruits and activates guanine nucleotide exchange factor RhoGEF ECT2 to 
the site of the cleavage furrow and this interaction is promoted by polo-like kinase 1 or Plk-1 
(Werner and Glotzer, 2008). This localized activation of ECT2 further leads to activation of 
RhoA at the cleavage furrow site, which is required for the actin-myosin contractile ring 
assembly. Thus, central spindle appears to control cytokinesis by localizing cytokinesis 
regulatory proteins to the midzone. Role of RhoA in the assembly of actin-myosin contractile 
ring will be discussed in detail below. Centralspindlin is not required for furrow initiation but is 
required for completion (von Dassow, 2009). Disruption of the spindle midzone can cause 
various types of cytokinesis defects depending upon the organism and the cell type (Glotzer, 
2004).  
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1.2.2 Step 2- Formation and ingression of an actin-myosin contractile ring  
After the site of the cleavage plane is determined, the next step of cytokinesis is the formation of 
an actin-myosin contractile ring. In eukaryotes, assembly and ingression of the contractile ring 
provides the mechanical force required for the separation of mother cell into two daughter cells 
during cytokinesis.  
               Early identification of filamentous structures at the cytokinetic furrow (Schroeder, 
1968) were later shown to contain F-actin and the molecular motor myosin (Fujiwara et al., 
1978; Schroeder, 1973). Actin and myosin are targeted to the cleavage furrow in a semi-
independent manner (Pollard, 2010). Myosin is assembled at the cleavage furrow in the form of 
membrane bound nodes (Vavylonis et al., 2008). Actin filament assembly at the cleavage furrow 
is promoted by the actin polymerizing protein formin (Chang et al., 1997) and the nucleating 
protein Arp2/3 (Pelham and Chang, 2002). Formin is also present in the discrete nodes that 
nucleate actin filaments. Once F-actin appears at the cleavage furrow, myosin captures and pulls 
the actin filaments intermittently from the adjacent nodes by a search and capture mechanism 
(Pollard, 2008). Thus, pulling of actin filaments by motor myosin condenses the nodes into a 
contractile ring. Once the ring is formed, it remains a dynamic structure with continuous 
assembly and disassembly of its components (Pelham and Chang, 2002). 
1.2.3 Step 3-Midbody formation  
Towards the end of cytokinesis, after the cleavage furrow ingression is completed, two dividing 
daughter cells remain connected by a thin cytoplasmic bridge. The core of the cytoplasmic 
bridge contains a phase-dense structure called a Fleming body or midbody. As the furrow 
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ingresses, it compacts the antiparallel bundles of midzone microtubules into a single large bundle 
that comprises the core of midbody. In addition to microtubules, the midbody contains several 
other proteins including centralspindlin components RhoA and anillin, proteins involved in 
vesicle trafficking and lipid rafts as well as chromosome passenger proteins and polo like kinase 
or Plk1 (Hu et al., 2012; Skop et al., 2004). The primary function of the midbody appears to be to 
localize the site of abscission.  
1.2.4 Step 4- Abscission  
The last step of cytokinesis is called abscission. This process is responsible for severing the 
residual thin cytoplasmic bridge formed after contraction, leading to complete separation of two 
daughter cells. This is probably the least well-understood step in cytokinesis and requires a cross 
talk between cytoskeletal, membrane trafficking and membrane remodeling processes.  
Abscission requires a series of complex events including vesicle transport and targeting, 
disassembly of midbody microtubules and plasma membrane fission/fusion. Three pathways of 
membrane trafficking: the secretory pathway, endocytic pathway and the components of the 
ESCRT (endosomal sorting complex required for transport) machinery are implicated in the 
process of abscission and blocking either of these pathways blocks cytokinesis (Gromley et al., 
2005; Schiel and Prekeris, 2010; Schweitzer et al., 2005). Golgi-derived secretory vesicles 
accumulate at the intercellular bridge during late stages of cytokinesis and the protein centriolin 
plays an important role in recruiting these vesicles (Gromley et al., 2005).  Recycling endosomes 
and other components of the endocytic pathway might be required during abscission to remodel 
the furrow plasma membrane as the furrow ingresses (Schweitzer et al., 2005) and endocytosis at 
the other parts of the cells such as polar region, might serve as a source of vesicles to be 
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delivered to the cleavage furrow. Recent studies have demonstrated that subunits of ESCRT 
machinery, conventionally known for their role in multivesicular body (MVB) formation, also 
play a role during late stage of cytokinesis. Components of ESCRT localize to the midbody and 
inhibition of some of the components blocks abscission (Dukes et al., 2008; Morita et al., 2007). 
Although precise role of these proteins in abscission is still elusive, as abscission requires a lot of 
membrane remodeling, understanding the role of ESCRT proteins in abscission would be 
interesting. After vesicle delivery at the midbody, membrane fusion is required to complete 
cytokinesis. SNARE proteins are critical for this process. Several SNARE proteins including 
Syntaxin 2 and VAMP - 8 are implicated in the process of abscission (Gromley et al., 2005; Low 
et al., 2003). Thus, the combined action of all the above-mentioned processes results in the 
resolution of intercellular cytoplasmic bridge and completion of cytokinesis. However, the 
precise spatial and temporal regulation of the process of abscission is just beginning to be 
understood. 
1.2.5 Regulation of cytokinesis  
All the stages of cytokinesis mentioned above are highly coordinated and tightly regulated to 
complete cytokinesis successfully. Being a central process, actin-myosin ring assembly is 
regulated at many different levels and regulation of myosin activity is probably one of the most 
important mechanisms of regulation of actin-myosin based contractile processes.  
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1.2.6 Regulation of myosin activity by myosin light chain phosphorylation  
Myosin is the motor protein that drives actin-based contractile processes and these processes are 
primarily regulated by the contractile activity of myosin. Myosins comprise of a super family of 
motor proteins that share the properties of ATP hydrolysis and actin binding (Yamashita et al., 
2000). They use the conformational changes driven by ATP hydrolysis to walk towards the 
positive or barbed ends of actin filaments. This walking slides the oppositely oriented actin 
filaments against each other, producing contraction. This process is central to all the contractile 
processes including skeletal, cardiac and smooth muscle contraction as well as the contractile 
processes in non-muscle tissues. More than 15 groups form the myosin superfamily labeled 
myosin I, myosin II, so on. Amongst these, myosin II, a conventional myosin, is the oldest 
member of the family, first discovered in skeletal muscle tissue (Yamashita et al., 2000). Since 
the discovery of the skeletal muscle isoform, myosin II has been shown to be ubiquitously 
expressed in skeletal, cardiac and smooth muscle as well as non-muscle cells and tissues. Non-
muscle myosin II (NM II) is expressed in almost all non-muscle cells and is essential for diverse 
contractile processes including cell adhesion, polarity, migration and division (Conti and 
Adelstein, 2008; De Lozanne and Spudich, 1987; Vicente-Manzanares et al., 2009). 
Interestingly, NM II is also expressed in muscle tissue where it regulates muscle tissue 
development and differentiation (Swailes et al., 2006).   
Myosin II, including muscle and non-muscle isoforms, are hexameric enzymes that 
comprise of a pair of heavy chains of 230 kDa, a pair of regulatory light chain (MLC) and a pair 
of essential light chains (ELC) of 20kDa each. The myosin heavy chain consists of head, neck, 
rod and tail domains (Weiss and Leinwand, 1996). The amino terminal portion of myosin heavy 
chain (MHC) contains the globular head or motor domain that possesses the ATPase activity and 
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the actin-binding site. A neck domain provides the attachment to regulatory and essential light 
chains and acts as a lever to amplify the head rotation during the conversion of chemical energy 
of ATP hydrolysis to mechanical energy. An elongated alpha-helical coiled coil rod domain and 
a short non-helical tail domain ajoin the neck domain. Coiled-coil rod domains can homo-
dimerise and form tail-to-tail bipolar filaments with motor heads at each end, unique to myosin II 
molecules.  
Three different genes encode non-muscle myosin heavy chain proteins - NMHC IIA, IIB 
and IIC respectively. Depending upon the heavy chain isoform, three different isoforms of NM II 
labeled as NM IIA, NM IIB or NM IIC are found in the mammalian tissues (Golomb et al., 2004; 
Simons et al., 1991).  Depending upon the cell type, different NM II isoforms show differences 
in the localization, however they are thought to have redundant functions.  
Regulation of myosin activity plays a central role in controlling actin-myosin interaction 
and reversible phosphorylation of myosin regulatory light chain or MLC is the major mechanism 
by which myosin activity is regulated (Moussavi et al., 1993; Sellers, 1991). MLC 
phosphorylation activates NM II in two ways. It increases Mg2+ATPase activity of the motor 
domain by changing conformation (Sellers et al., 1981; Wendt et al., 2001), and enhances 
filament-forming ability of coiled coil tail domain of the heavy chain (Scholey et al., 1980). 
(Figure 3) 
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Figure 3. Regulation of myosin II activity by MLC phosphorylation.  
Myosin II consists of a pair of heavy chains, a pair of essential light chains (ECL) and a pair of 
regulatory light chains (MLC). When MLC is unphosphorylated, myosin II is folded into a compact 
structure. Phosphorylation of MLC on active sites results in the unfolding of the tail domain that can 
dimerize to form the bipolar filaments. Phosphorylation of MLC also increases the ATPase activity of the 
head domain. Activated myosin then can interact with actin, leading to contraction.  
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In the unphosphorylated state, NM II is folded into a compact structure as the tail of 
unphosphorylated NM II is folded at two points and physically interacts with the head domain to 
make it compacted. Further, under unphosphorylated conditions, one head blocks another head 
of the same molecule from binding to actin. Phosphorylation of MLC disrupts head-head and 
head-tail interaction enabling the unfolded tail domain to dimerize and form bipolar filaments. 
Phosphorylation of MLC at Ser19 is the predominant activating phosphorylation as it enhances 
the ATPase activity and promotes the filament assembly of myosin (Ikebe and Hartshorne, 1985; 
Pearson et al., 1984). Ser19 phosphorylation is sometimes followed by another activating 
phosphorylation at Thr18 residue, which further increases the filament forming ability of myosin 
(Ikebe, 1989; Ikebe et al., 1986). MLC can also be phosphorylated on Thr9 and Ser1 and Ser2 
(Bengur et al., 1987). However, these phosphorylation events are inhibitory and decrease the 
Mg2+ATPase activity of myosin (Nishikawa et al., 1984). 
 It is well established that MLC phosphorylation is cell cycle regulated. In metaphase, 
MLC is predominantly phosphorylated on inhibitory sites Ser1/2. However, as the cell 
progresses through anaphase, MLC is de-phosphorylated on these sites and phosphorylated on 
Ser19, thus activating myosin during anaphase (Yamakita et al., 1994). Interestingly Ser19 
phosphorylation immediately precedes the formation of the cleavage furrow and antibody 
staining demonstrates that MLC phosphorylated on Ser19 localizes to the cleavage furrow 
(Matsumura et al., 1998). All these data indicate that MLC phosphorylation of Ser19 is crucial 
for the process of cytokinesis.  
Referring its importance in myosin regulation, MLC can be phosphorylated by a variety 
of kinases and a single known phosphatase (Matsumura, 2005; Matsumura et al., 2011). The 
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following section describes the role of these enzymes in regulating MLC phosphorylation, 
specifically during cytokinesis.  
1.2.7 Myosin light chain kinase 
As the name suggests, myosin light chain kinase or MLCK is a dedicated MLC kinase with MLC 
as its only known substrate (Kamm and Stull, 2001). MLCK phosphorylates MLC primarily on 
Ser19 and to a lesser extent on Thr18, thus it activates both the ATPase activity of the motor 
domain and promotes the biopolar filament assembly of myosin II (Ikebe and Hartshorne, 1985; 
Pearson et al., 1984).  
MLCK is a ubiquitously expressed enzyme encoded by three genes in humans: mylk1, 
mylk2 and mylk3. Mylk2 encodes a skeletal muscle specific isoform whereas mylk3 encodes a 
cardiac specific isoform (Chan et al., 2008; Zhi et al., 2005). The mylk1 gene encodes smooth 
muscle and non-muscle isoforms (Gallagher et al., 1991). Non-muscle isoform is widely 
expressed, and is detectable in most tissue and cell types. It regulates MLC phosphorylation 
during a variety of non-muscle contractile processes such as cell spreading, cell migration, focal 
adhesion, stress fiber formation, neurite growth cone advancement, apoptotic blebbing, secretion 
and cytokinesis, to name a few (Kamm and Stull, 2001). Using an alternative promoter, the 
mylk1 gene encodes three different MLCK isoforms (Birukov et al., 1998). The long isoform 
(MW~220KDa, also named non-muscle or long MLCK) is ubiquitously expressed during 
development, but in adults it is predominantly expressed in non-muscle tissues (Blue et al., 
2002). The short isoform (MW~108-130KDa, also called smooth muscle or short MLCK) is 
predominantly expressed in smooth muscles during development and maturity. A third transcript 
(MW~24 KDa, called telokin or kinase related protein- KRP) is a non-catalytic isoform and 
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lacks the kinase domain (Ito et al., 1989). In a non-muscle tissue, the long and the short isoform 
demonstrate distinct localization patterns. The short isoform is diffusely distributed throughout 
the cytoplasm whereas the long isoform specifically localizes to stress fibers and also to the 
cleavage furrow during cell division. Thus, the long isoform plays a distinct role during both, the 
assembly and the ingression of the actin-myosin contractile ring (Poperechnaya et al., 2000). 
1.2.7.1 Structure function relationship of MLCK 
MLCK enzymes are the members of the immunoglobulin super family of proteins. All 
the isoforms of MLCK are calcium and calmodulin dependent enzymes (Yagi et al., 1978) and 
there is no evidence for MLCK activity independent of Ca2+/calmodulin. MLCK contains a 
conserved kinase domain and a regulatory segment located to the C-terminal of the kinase 
domain (Figure 4).  
 
 
 
Figure 4. A schematic of MLCK structure.  
Both the long and the short isoforms of MLCK consist of a conserved kinase domain and a C-
terminal regulatory domain. The regulatory domain contains an autoinhibitory domain that connects the 
 31 
calmodulin-binding domain to the kinase domain. The long isoform is identical to the short isoform except an 
922-934 amino acid extension at the N-terminus that contains two additional actin binding domains and six 
IgG modules. 
The regulatory domain consists of an autoinhibitory domain that connects the 
calmodulin-binding domain to the kinase domain (Padre and Stull, 2000). In the absence of 
Ca2+/calmodulin, the autoinhibitory domain folds back on the catalytic core and prevents the 
binding of MLC, but not of ATP, to the catalytic cleft. Calmodulin binding results in the 
displacement of the autoinhibitory domain from the catalytic cleft, with subsequent binding of 
the N-terminal of MLC to the catalytic cleft and transfer of the terminal phosphate of ATP to 
MLC (Kamm and Stull, 2001). The telokin domain is present on the C-terminus of the regulatory 
segment and facilitates binding of unphosphorylated MLC (Shirinsky et al., 1993). Other than 
the conserved kinase domain and a regulatory segment, short isoform of MLCK consists of one 
Fn module, three IgG modules, a PEVK repeat rich region and an actin binding domain 
consisting of three DFRXXL repeat motifs at the N-terminal of the kinase domain (Hong et al., 
2011; Kamm and Stull, 2001). Thus, MLCK appears to be anchored to actin at its N-terminus 
and the catalytic core at the C-terminus is exposed to myosin filaments for MLC 
phosphorylation.  The long isoform of MLCK is identical to the short isoform except an 922-934 
amino acid extension at the N-terminal that contains two additional actin binding domains and 
six IgG modules (Garcia et al., 1997). The additional IgG modules in the long isoform contribute 
to its targeting to stress fibers and the cleavage furrow (Dulyaninova et al., 2004; Poperechnaya 
et al., 2000).  
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1.2.8 Regulation of MLCK activity by phosphorylation by Aurora B kinase 
In addition to Ca2+/calmodulin, non-muscle MLCK activity can be modulated by a variety of 
signaling pathways that regulate cytoskeletal morphology during cell motility, migration and 
division. Upstream kinases that phosphorylate non-muscle MLCK during different times include 
growth factors such as mitogen activated kinases (MAPK) ERK1 and ERK2 (Klemke et al., 
1997), Src kinase (Garcia et al., 1999), cAMP dependent protein kinase - PKA (Horman et al., 
2008), Rho family GTPases p21-activated kinase PAK2 and PAK1 (Goeckeler et al., 2000) and 
Aurora B kinase (Dulyaninova and Bresnick, 2004). Phosphorylation of MLCK by different 
kinases is required for the regulation of different processes such as cell spreading, stress fiber 
formation, cell migration, cell division and cytokinesis. 
Perhaps the most relevant kinase that controls MLCK activity during cytokinesis is a 
known regulator of cytokinesis - Aurora B kinase (Dulyaninova and Bresnick, 2004). MLCK 
activity varies during the cell cycle. It is lower during early mitosis but increases almost two-fold 
during cytokinesis (Poperechnaya et al., 2000). This variation in MLCK activity correlates very 
well with the phosphorylation status of MLC during cytokinesis, suggesting that MLCK is the 
key kinase that phosphorylates MLC during cytokinesis. However, the upstream signals that 
regulate MLCK phosphorylation and activity temporally and spatially are not completely 
understood at this point. Consistent with the changes in its activity, the long isoform of MLCK is 
differentially phosphorylated, predominantly on serine residues during the cell cycle 
(Dulyaninova and Bresnick, 2004). Interestingly, Aurora B binds to long MLCK in vitro and 
phosphorylates serine residues in the IgG modules. Considering the specific localization of long 
MLCK to the cleavage furrow and the crucial role of Aurora B in regulating cytokinesis, it can 
be proposed that phosphorylation of MLCK by Aurora B is a key regulatory event during 
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cytokinesis. However the significance of this phosphorylation and its effect on MLCK activity 
are not yet clear and need to be investigated further to study the normal process of cytokinesis 
and also to understand the causes of its failure.  
1.2.9 MLC phosphorylation by other kinases and a phosphatase 
Another important regulator of actin-myosin assembly and contraction is the small GTPase 
RhoA. RhoA is activated by RhoGEF-ECT2 (Yuce et al., 2005). During anaphase, ECT2 is 
localized to the central spindle and interacts with the centralspindlin component CYK-
4/MgcRacGAP. This interaction stabilizes ECT2 in an active conformation allowing it to 
activate RhoA (Yuce et al., 2005). Restriction of the centralspindlin component to the central 
spindle thus limits localization of ECT2 and the activation of RhoA to a narrow zone during 
furrow formation. Cyk-4/MgcRacGAP is a GTPase activating protein (GAP) for RhoA. In 
addition to activating ECT2, Cyk-4/MgcRacGAP is also thought to inactivate RhoA late in 
cytokinesis, along with another GAP protein p190RhoGAP (Su et al., 2003). 
Activated RhoA regulates myosin assembly by activating its downstream targets Rho-
dependent kinase (ROCK) and Citron kinase (Citron K). ROCK can directly activate myosin by 
phosphorylating MLC on Ser19 (Amano et al., 1996). ROCK also indirectly activates myosin by 
inhibiting myosin binding subunit (MBS) of myosin phosphatase that takes off the activating 
phosphorylation of myosin (Kimura et al., 1996). Citron Kinase, another effector protein of 
RhoA, can phosphorylate MLC on Thr18 and Ser19 (Yamashiro et al., 2003). ROCK is required 
for the ingression of the cleavage furrow whereas Citron kinase is required for the maintenance 
of the cleavage furrow and completion of cytokinesis. Death associated protein kinase (DAPK) 
and DAPK-like kinase, known as DAPK3 also appear to regulate MLC phosphorylation during 
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cytokinesis. However, the detailed role of these kinases in cytokinesis is not yet known (Preuss 
et al., 2003). 
In contrast to the redundant kinases, there is a single known phosphatase that de-
phosphorylates MLC (Matsumura et al., 2011). Myosin phosphatase consists of a large targeting 
subunit known as MYPT1, a catalytic subunit known as PP1c and a small subunit (Hartshorne et 
al., 2004). It is interesting to note that many kinases such as ROCK which phosphorylate MLC, 
can also phosphorylate and inhibit myosin phosphatase (Hartshorne et al., 2004).  
1.2.10 Regulation of cytokinesis by Aurora B kinase 
All the stages of cytokinesis are regulated by Aurora B kinase, a member of a conserved 
serine/threonine kinase family. Aurora kinases were first identified in Drosophila melanogaster 
during the search for the genes that regulate structure and function of mitotic spindle (Glover et 
al., 1995) and are homologous to the Saccharomyces cerevisiae Ipl-1 (Francisco et al., 1994). So 
far three members have been identified in the human Aurora family namely, Aurora A, Aurora B 
and Aurora C (Adams et al., 2001). Aurora A primarily functions in centrosome maturation and 
separation. Aurora B kinase regulates kinetochore-microtubule attachments, spindle assembly 
checkpoint and cytokinesis. Aurora C appears to function redundantly with Aurora B, however 
its function is not yet well understood.  
1.2.10.1 Aurora kinases and cancer  
Interestingly, human Aurora kinase family members Aurora A and B were first identified 
as homologs of fly aurora kinases in a PCR screen performed for kinases over-expressed in 
colorectal cancer (Bischoff et al., 1998). Since then, both Aurora A and Aurora B are found to be 
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over-expressed in a majority of tumor tissues. Unlike Aurora A, Aurora B gene amplification has 
not been clearly demonstrated and it is usually not classified as a classical oncogene. 
Nonetheless, a variety of tumor tissues over-express Aurora B including colon, prostate, thyroid, 
liver, breast, and lung cancer to name a few (Chieffi et al., 2006; Katayama et al., 2003; Lin et 
al., 2010; Mountzios et al., 2008; Qi et al., 2007; Sorrentino et al., 2005). Although Aurora B 
cannot transform cells on its own, it potentiates Ras-mediated transformation (Kanda et al., 
2005). Elevated levels of Aurora B are a predictor of poor cancer prognosis and positively 
correlate with advanced stages of cancer progression (Kurai et al., 2005) and increased genomic 
instability (Smith et al., 2005).  Many Aurora B inhibitors are currently in phase I and phase II 
clinical trials as chemotherapeutic agents and are showing promising results (Kollareddy et al., 
2012).  
1.2.10.2 Mitotic functions of Aurora B 
Aurora B regulates mitosis as a component of the chromosomal passenger complex 
(CPC). Core CPC components include Aurora B kinase and non-enzymatic subunits include 
inner centromere protein –INCENP, survivin and borealin (Ruchaud et al., 2007). Aurora B 
binds to a region near the C-terminus of INCENP called the IN box. This binding leads to auto-
phosphorylation of Aurora B and is necessary for its activity. Activated Aurora B then 
phosphorylates INCENP leading to a further increase in its kinase activity in a positive feed-back 
loop (Bishop and Schumacher, 2002; Yasui et al., 2004). Survivin and borealin are also 
substrates of Aurora B and appear to function in targeting of CPC to different locations during 
mitosis (Gassmann et al., 2004; Wheatley et al., 2004).  
As the name suggests, being a part of CPC, Aurora B demonstrates very dynamic 
localization during cell division (Murata-Hori et al., 2002). It associates with chromosome arms 
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very briefly but concentrates at the inner centromeric region through prometaphase and 
metaphase. At the onset of anaphase, Aurora B redistributes from chromatin to the spindle 
midzone and is concentrated at the equator along with the midzone microtubules, whereas during 
late anaphase it concentrates at the midbody (Murata-Hori et al., 2002; Terada et al., 1998). 
Known Aurora B functions correlate well with this dynamic localization of Aurora B 
during mitosis. During early mitosis, prior to the onset of anaphase, Aurora B localizes to the 
chromosome arms and the centromeric region and regulates chromosome condensation, sister 
chromatid cohesion, kinetochore-microtubule attachment error correction and spindle assembly 
checkpoint. Aurora B regulates chromosome condensation by phosphorylating Histone H3 on 
serine 10 (Hsu et al., 2000). It is required for the recruitment of condensin on the chromosomes 
in some organisms (Giet and Glover, 2001) and for confining the localization of the Shugoshin 
family of proteins that are required for maintaining sister-chromatid cohesion (Resnick et al., 
2006).  
For accurate chromosome segregation, all sister chromatids need to attach to the 
microtubules emanating from the opposite spindle poles. Aurora B plays an important role in 
establishing kinetochore-microtubule attachments by phosphorylating kinetochore-associated 
proteins such as Ncd80/Hec-1 and Dam1 complexes in yeast (Cheeseman et al., 2002). In 
addition to establishing normal bipolar attachments, Aurora B plays a pivotal role in correcting 
erroneous merotelic or syntelic kinetochore-microtubule attachments. Aurora B is enriched at the 
site of merotelic attachments and destabilizes them by activating depolymerase MCAK that leads 
to depolymerization of incorrectly attached microtubules (Knowlton et al., 2006). Even a single 
unattached or incorrectly attached kinetochore activates spindle assembly checkpoint (SAC).  
SAC delays the onset of anaphase by inhibiting the activation of anaphase promoting complex 
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(APC) by formation of inhibitory complexes of MAD and BUB proteins, until correct bivalent 
orientation of chromosomes is achieved (Musacchio and Salmon, 2007) (Rieder et al., 1995; 
Wassmann and Benezra, 2001). SAC is activated either due to the absence of tension between 
the sister chromatids or the presence of unattached chromatids. Aurora B appears to activate 
SAC by sensing the absence of tension in the presence of incorrect kinetochore-microtubule 
attachments (Musacchio, 2011).  
1.2.10.3 Aurora B as a regulator of cytokinesis 
During late mitosis, Aurora B localizes to the spindle midzone and midbody and 
primarily functions to regulate cytokinesis. Interestingly, the predominant phenotype of Aurora 
B mis-regulation is cytokinesis failure and induction of multinucleation and polyploidy. 
Exogenous over-expression of Aurora B in rat cells, human cells or the Chinese hamster ovary 
cells results in defective cleavage furrow formation, cytokinesis failure and polyploidy (Tatsuka 
et al., 1998; Terada et al., 1998). Conversely, complete depletion of Aurora B by siRNA or by 
chemical inhibition also results in cytokinesis failure and multinucleation (Ditchfield et al., 2003; 
Tsuno et al., 2007). Thus, optimal levels of Aurora B appear to be essential for successful 
cytokinesis. Aurora B over-expressing cells form tumors upon injection into nude mice (Nguyen 
et al., 2009; Ota et al., 2002). Interestingly, tumors formed upon injection of Aurora B over-
expressing tetraploid cells are larger than those formed upon injection of their diploid 
counterparts (Nguyen et al., 2009). Moreover, these tumors are metastatic and the tumor cells are 
multinuclear, aneuploid and show various degrees of chromosome amplifications and deletions 
(Nguyen et al., 2009; Ota et al., 2002). Thus, cytokinesis failure and tetraploidy induction 
appears to be the underlying mechanism of Aurora B–induced tumorigenesis.  
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Although Aurora B mis-regulation phenotype clearly demonstrates its necessity during 
cytokinesis, the precise molecular mechanism by which Aurora B regulates cytokinesis is not yet 
clearly understood. Considering the tumorigenic potential of Aurora B over-expressing tetraploid 
cells and promising results of Aurora B inhibitors as therapeutic targets, it is necessary to 
understand in detail the role of Aurora B in cytokinesis regulation. 
A substrate profile of Aurora B kinase indicates that Aurora B spatially and temporally 
regulates cytokinesis by phosphorylating different substrates at different stages of the process. At 
the onset of anaphase a phosphorylation gradient of Aurora B substrates is established at the 
spindle midzone through interaction of Aurora B with midzone microtubules in a positive 
feedback loop (Fuller et al., 2008). At the midzone, Aurora B phosphorylates the centralspindlin 
component MgcRacGAP, thus regulating RhoA activity during establishment of the cleavage site 
and the initiation of the cleavage furrow ingression (Minoshima et al., 2003). Interestingly, 
Aurora B dependent NoCut pathway negatively regulates abscission by delaying it in the 
presence of un-segregated chromatin (Norden et al., 2006; Steigemann et al., 2009). So far, 
MKLP-1 and ESCRT-III component CHMP4C are identified as Aurora B substrates that are 
involved in abscission inhibition (Carlton et al., 2012). However, future work is required to 
uncover additional Aurora B targets that might be involved in cytokinesis regulation. Other 
substrates of Aurora B that localize to the cleavage furrow and might be important targets during 
cytokinesis include vimentin, desmin, glial fibrillary acidic protein and MLCK (Dulyaninova and 
Bresnick, 2004; Goto et al., 2003; Minoshima et al., 2003).  
We are specifically interested in understanding the significance and consequences of 
phosphorylation of MLCK by Aurora B. Aurora B phosphorylates MLCK on serine residues, 
predominantly located within its IgG modules (Dulyaninova and Bresnick, 2004). This 
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phosphorylation matches well the changes in MLCK activity and MLC phosphorylation status 
during cell cycle. As described later, taking into account the necessity of MLCK for MLC 
phosphorylation during cytokinesis, we aim to study in detail the effect of Aurora B kinase on 
MLCK activity. This dissertation project provides specific insights into the role of MLCK as an 
Aurora B substrate and the effect of Aurora B mis-regulation on MLCK activity and on 
cytokinesis outcomes in cancer cells.  
1.3 DISSERTATION OVERVIEW 
Research performed over the past few decades makes it clear that tetraploidy plays a causal role 
in genomic instability, transformation and neoplasia. However, further investigations are 
required to address the causes of tetraploidy and to uncover the mis-regulated pathways that 
under normal circumstances maintain the diploid status of the cells. These studies will also 
provide novel drug targets for efficient chemotherapy.   
Previous studies in our laboratory, performed to identify the causes of tetraploidy in 
cancer cells, reveal that cytokinesis failure is the primary source of tetraploidy in cancer cells. 
These cells specifically fail to maintain actin-myosin based contraction at the cleavage furrow, 
resulting in cleavage furrow regression and cytokinesis failure. Actin-myosin contraction is 
tightly regulated by the phosphorylation of MLC and our studies identify deficient MLC 
phosphorylation as the cause of cytokinesis failure in cancer cells. The first goal of this 
dissertation project is to dissect the upstream pathways that lead to deficient MLC 
phosphorylation in cancer cells. Given the oncogenic potential and frequently observed mis-
regulation of Aurora B kinase in cancer cells, we have explored the role of Aurora B mis-
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regulation in cytokinesis failure. For this study, the most relevant substrate of Aurora B is 
MLCK, a kinase that regulates MLC phosphorylation during cytokinesis and is inhibited in 
cancer cells. Therefore, we hypothesize that Aurora B mis-regulation causes cytokinesis failure 
by inhibition of MLCK. Chapter 2 of this dissertation explains in details the results that led us to 
this hypothesis and the data that support it. 
Our previous study reported abortive cytokinesis in approximately 10% of the cancer cell 
population, depending on the cancer cell type (Wu et al., 2010a). These observations are 
intriguing, as the cytokinesis failure appears to occur only in a certain fraction of the population. 
Whether this fraction fails in cytokinesis randomly or there is an underlying anomaly that 
predisposes only a subset of cells to fail is not known at this stage. Therefore, the second goal of 
this dissertation project is to understand the reasons as to why cytokinesis fails only in a subset 
of the cells. Chromosome segregation errors are frequently observed in cancer cells and are 
proposed to cause cytokinesis failure. Therefore we hypothesize that chromosome segregation 
errors act as a trigger for mis-regulation of Aurora B, inhibition of MLCK and cytokinesis failure 
in cancer cells. Chapter 3 of this dissertation explains in detail the rationale behind this 
hypothesis and the results supporting it.  
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2.0  INHIBITION OF MLCK BY AURORA B KINASE CAUSES CYTOKINESIS 
FAILURE IN CANCER CELLS 
2.1 INTRODUCTION  
As described in the Introduction (Chapter 1, section 1.1), tetraploidy in some cell types poses a 
serious threat in terms of the cellular transformation and tumorigenesis. Studies undertaken to 
identify the causes of tetraploidy point to cytokinesis failure as the primary cause of tetraploidy 
generation (Steigemann et al., 2009; Wu et al., 2010a). Cytokinesis failure doubles the number of 
chromosomes and centrosomes. Both of these events lead to an increase in the incidence of 
chromosome mis-segregation, aneuploidy and tumorigenesis. However the causes of cytokinesis 
failure are still not completely understood. Investigation into identifying the pathways that 
culminate in failed cytokinesis will give us further insights into the course of tetraploidy induced 
tumorigenesis.  
Cytokinesis in animal cells is accomplished by the formation and ingression of the 
cleavage furrow composed of an actin-myosin contractile apparatus. The contractile ability of 
this apparatus is highly dependent on the phosphorylation of myosin regulatory light chain or 
MLC. MLC phosphorylation is necessary to induce bipolar filament assembly and increase in the 
ATPase activity of motor myosin. Thus, MLC phosphorylation controls both the assembly and 
contractility of the actin-myosin apparatus.   
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Not surprisingly, spatial and temporal regulation of cytokinesis depends on the 
phosphorylation status of MLC. During cytokinesis, MLC is phosphorylated at Thr18 and Ser19 
residues and phosphorylation at these sites is indispensible for the process. Expression of an 
unphosphorylatable mutant of MLC (T18A/S19A) in mammalian cells results in distorted 
cleavage furrow formation, cytokinesis failure and a significant increase in the formation of 
multinuclear cells (Komatsu et al., 2000). Similarly, Drosophila clones expressing 
unphosphorylatable MLC (T20A/S21A, corresponding MLC phosphorylation sites in 
Drosophila) cannot perform cytokinesis and have a phenotype almost identical to MLC null flies 
(Jordan and Karess, 1997). Consistently, live cell-imaging analysis of cancer cells report 
cytokinesis failure at an early stage, as a result of abnormal contractility of actin-myosin at the 
cleavage furrow (Wu et al., 2010a). Based on these data, we hypothesize that cancer cells fail in 
cytokinesis because of deficiencies in MLC phosphorylation. 
2.2 DEFICIENT MLC PHOSPHORYLATION IS THE CAUSE OF CYTOKINESIS 
FAILURE IN CANCER CELLS 
2.2.1 MLC phosphorylation is reduced in cancer cells and correlates with the 
multinucleation frequency  
To test the hypothesis of MLC phosphorylation deficiency as the cause of cytokinesis failure in 
cancer cells, we compared MLC phosphorylation status between a panel of non-cancer control 
cell lines and cancer cell lines. As described previously, the unphosphorylated form of MLC (un-
pMLC) was separated from monophosphorylated (mono-pMLC) and diphosphorylated (di-
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pMLC) forms using urea glycerol gel electrophoresis (Word et al., 1991). After measuring the 
band intensities, MLC phosphorylation ratios were calculated as a ratio of (mono-pMLC+di-
pMLC) / (un-pMLC+mono-pMLC+di-pMLC). Consistent with our hypothesis, non-cancer cells 
showed significantly higher phosphorylation ratios compared to cancer cells (p < 0.001) (Figure 
5A) (Wu et al., 2010a). Lower phosphorylation ratios were relevant to cytokinesis, as MLC 
phosphorylation was induced at similar times in mitosis in non-cancer and cancer cells but 
remained lower in cancer cells even after normalizing the percentage of cells in anaphase (Wu et 
al., 2010a). Cytokinesis failure is the origin of multinucleated tumor cells. Therefore we tested if 
there was a correlation between MLC phosphorylation ratio and the frequency of multinucleated 
cells. As expected, non-cancer cells that possessed high MLC phosphorylation ratio had a low 
frequency of multinucleated cells. In contrast, cancer cells that demonstrated a low MLC 
phosphorylation ratio had a higher frequency of multinucleation and the correlation was 
statistically valid (Figure 5B) (Wu et al., 2010a). These data suggest that cancer cells are 
deficient in MCL phosphorylation and this deficiency correlates with the observed cytokinesis 
failure.   
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Figure 5. MLC phosphorylation is reduced in cancer cells and correlates with the multinucleation 
frequency.  
(A) MLC phosphorylation levels were compared between a panel of asynchronous non-cancer and 
cancer cells by urea glycerol gel electrophoresis. MLC Phosphorylation ratio = (mono-pMLC+dipMLC)/(un-
MLC+mono-pMLC+dipMLC). Un-pMLC= unphosphorylated MLC, mono-pMLC= MLC phosphorylated at 
a single residue and di-pMLC= MLC phosphorylated at both the residues.  Error bars represent mean±S.D 
from more than three experiments, p < 0.001. (B) The ratio of MLC phosphorylation was correlated with the 
frequency of multinucleation in the indicated cell lines. Diamonds represent non-cancer cells and circles 
represent cancer cells (Wu et al., 2010a).  
2.2.2 Deficient MLC phosphorylation is the cause of cytokinesis failure in cancer cells  
To test if MLC phosphorylation deficiency played a causal role in cytokinesis failure, we 
examined cytokinesis failure after transfection of a phosphomimetic MLC construct tagged with 
GFP (Ward et al., 2002). This construct consists of an aspartic acid residue at the position 18 and 
19 (T18D/S19D) instead of WT threonine and serine and will hereafter referred to as GFP-
MLCDD. As MLC is predominantly phosphorylated on T18/S19 during cytokinesis, this 
construct mimics phosphorylated state of MLC during cell division, bypassing the need for its 
upstream regulators. The mutant protein expressed abundantly and localized correctly at the 
cleavage furrow (Figure 6A). In this and all the subsequent experiments, multinucleation or 
binucleation frequency was counted by staining the cells with DAPI to mark the nuclei and actin 
to denote the cell boundary. 48 hours after transfection of the phosphomimetic plasmid, 
moderate but statistically significant decrease in the frequency of multinucleation was observed 
in all the four cancer cell lines tested (Figure 6B) (Wu et al., 2010a). These observations were 
also confirmed by imaging the oral cancer cell line UPCI:SCC103 in real time with both DIC 
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and fluorescent markers (Wu et al., 2010a). MLC is de-phosphorylated by a single known 
phosphatase. Increasing MLC phosphorylation by knock-down of myosin targeting subunit of 
myosin phosphatase, known as MYPT1 also resulted in a reduction in the multinucleation and 
thus rescued cytokinesis failure in cancer cells (Wu et al., 2010a). Taken together, all these data 
support our hypothesis that deficient MLC phosphorylation is the cause of cytokinesis failure in 
all the tested cancer cell lines.  
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Figure 6. Phosphomimetic MLC reduces cytokinesis failure in cancer cells.  
(A) A representative image of the correct localization of phosphomimetic MLC (GFP-MLCDD) at 
the cleavage furrow of the dividing cell. DAPI stain indicates nuclei. (B) Multinucleation frequency was 
measured after 48 hours of transient transfection of phosphomimetic MLC in the indicated cancer cell lines. 
Data includes mean±SD from three independent experiments and n > 500 cells for each experiment (Wu et 
al., 2010a). 
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2.3 MLCK IS INHIBITED IN CANCER CELLS AND THIS INHIBITION IS THE 
CAUSE OF CYTOKINESIS FAILURE  
2.3.1 MLCK is expressed at low levels in cancer cells 
Establishing deficient MLC phosphorylation as the cause of cytokinesis failure led us to our next 
task of identification of the sources of deficient MLC phosphorylation in cancer cells. Reflecting 
the robustness of the process of cytokinesis, MLC phosphorylation is controlled redundantly by 
many kinases and a single phosphatase (Matsumura, 2005; Matsumura et al., 2011), described in 
detail in the Introduction.  
Out of these kinases, MLCK is the key kinase that phosphorylates MLC. During 
cytokinesis, MLC is phosphorylated by MLCK predominantly on Ser19 and to a lesser extent on 
Thr18 (Ikebe and Hartshorne, 1985). This phosphorylation appears to be essential for the 
completion of cytokinesis as demonstrated by studies in different model systems. In sea urchin 
embryos, MLCK dependent MLC activity precedes cleavage furrow formation and is maintained 
throughout cytokinesis (Lucero et al., 2006). During fly spermatogenesis, MLCK is required for 
contractile ring contraction at all the stages of cytokinesis and MLCK inhibition causes cleavage 
furrow regression and cytokinesis failure (Silverman-Gavrila and Forer, 2001; Wong et al., 
2007). MLCK inhibition in non-cancer cells also results in reduced MLC phosphorylation and a 
significant increase in multinucleation (Wu et al., 2010a). All of these results suggest that MLCK 
is indispensible for MLC phosphorylation during cytokinesis. Consistent with the role of MLCK 
during cytokinesis and the observed cytokinesis failure in cancer cells, MLCK is down-regulated 
in some cancer cell types such as prostate and colon cancer (Lee et al., 2008; Leveille et al., 
2009).  
 50 
Therefore, to test if MLCK down-regulation was the cause of cytokinesis failure in 
cancer cells, we compared MLCK protein levels by immunoblotting across the panel of different 
cancer and non-cancer cell lines and expectedly found them to be lower in cancer cells as 
compared to non-cancer cells (Figure 7A). However, cancer cells have higher mitotic indices 
compared to non-cancer cells. To rule out the possibility of cell cycle differences between cancer 
and non-cancer cells as the underlying cause of the observed MLCK down-regulation, MLCK 
levels were examined in cell cycle synchronized non-cancer cells RPE1 and oral squamous cell 
carcinoma cells UPCI:SCC103. This pair of non-cancer and cancer cell line was chosen for their 
compatibility with cell cycle synchronization and their common epithelial origin. Nocodazole 
was used to arrest cells in mitosis, as it is a drug that depolymerizes microtubules, thus inhibiting 
the formation of mitotic spindle and arresting cells in mitosis. MLCK expression was then 
compared in mitotically arrested cells as well as cells released form the arrest for four hours. 
Even at the comparable mitotic indices, MLCK expression remained lower in cancer cells as 
compared to non-cancer cells (Figure 7B), confirming low abundance of MLCK in cancer cells 
independent of the cell cycle differences.  
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Figure 7. MLCK is expressed at lower levels in cancer cells.  
(A) MLCK protein levels in the indicated asynchronous non-cancer and cancer cells were determined 
by immunoblotting. L and S represent the long and the short isoform of MLCK respectively. Actin was used 
as a loading control. (B) MLCK expression was compared between cell cycle synchronized RPE1 (non-
cancer) and UPCI:SCC103 (cancer) cells. Cells were arrested in mitosis with nocodazole and released for four 
hours. Different concentrations of nocodazole (400ng/ml for RPE1 and 300ng/ml for UPCI:SCC103 were 
used to achieve comparable mitotic indices. Bottom row indicates mitotic indices (MI) as percentage of cells in 
mitosis judged by DAPI staining and epifluorescence microscopy (n > 500).  
2.3.2 MLCK activity is inhibited in cancer cells  
It is possible that the low abundance of MLCK, as described above, is the cause of deficient 
MLC phosphorylation and cytokinesis failure in cancer cells. If this is true, exogenous 
expression of MLCK should increase MLC phosphorylation and rescue cytokinesis defects. To 
test this possibility we over-expressed a WT MLCK-GFP construct in cancer cell line 
UPCI:SCC103. The construct was shown to be active and exogenous protein expressed at 
abundant levels. However surprisingly, in spite of increasing the protein abundance, MLC 
phosphorylation did not increase and we did not observe a reduction in cytokinesis defects (Wu 
et al., 2010a). This suggested that in addition to its lower abundance, MLCK kinase activity is 
inhibited in cancer cells.   
To test this hypothesis, I examined MLCK activity by an in vitro kinase assay.  The assay 
was performed as described previously using a synthetic peptide substrate and the activity was 
measured as pMoles of ATP transferred to the substrate (Y axes) over a period of time (X axis) 
(Poperechnaya et al., 2000). First of all, the specificity of the assay was confirmed. As described 
in the Introduction, MLCK is a calmodulin-dependent enzyme. When MLCK activity was 
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measured in the presence and absence of calmodulin, no activity was detected in the absence of 
calmodulin, indicating the measurement of a calmodulin-dependent enzyme activity (Figure 8A). 
Kinase activity was also undetectable in the presence of MLCK inhibitor ML-7, which 
specifically inhibits the catalytic activity of MLCK (Saitoh et al., 1987)(Figure 8B). MLCK is 
known to autophosphorylate (Foyt and Means, 1985). However, no phosphorylation was 
detected in the absence of a substrate, ruling out the possibility of MLCK autophosphorylation as 
a source of the measured counts (Figure 8C). Taken together, all these controls confirm that the 
in vitro kinase assay was specifically measuring MLCK activity and was only detecting peptide 
substrate phosphorylation.  
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Figure 8. Specificity of the in vitro kinase assay.   
Specificity of the in vitro kinase assay, used to measure MLCK activity, was ensured by three 
different controls. (A) Kinase assay values were determined in the presence and the absence of calmodulin to 
ensure the measurement of the activity of a calmodulin dependent enzyme. (B) Kinase assay was performed 
after the addition of MLCK specific inhibitor ML-7. (C) Kinase assay values were measured in the presence 
and the absence of a synthetic peptide substrate to rule out the possibility of MLCK autophosphorylation 
being detected as the phosphorylation counts. In this and all the subsequent kinase assays, Y-axis indicates 
transfer of a radiolabeled phosphate from ATP to a peptide MLCK substrate and X-axis indicates a time 
period after the start of the reaction. Irregularities in some data points indicate performer’s error as these 
experiments were performed during the optimization of the kinase assay. 
 
After confirming the specificity of the kinase assay, I measured the kinase activity of 
MLCK purified from non-cancer and cancer cells. Equal amounts of MLCK were 
immunoprecipitated form RPE1 and UPCI:SCC103 cells. In this and all the subsequent kinase 
assay experiments, half of the immunoprecipitates were used for immunoblotting to confirm 
MLCK immunoprecipitation and the other half was used for the kinase assay. Immunoblots were 
also quantified using an image-processing program ‘Image J’ and minor adjustments (<10%) 
were given to the kinase assay values to account for any differences in the immunoprecipitation 
efficiencies. Results of the in vitro kinase assay indicated that MLCK purified from cancer cells 
UPCI:SCC103 was less active as compared to MLCK purified from non-cancer cells RPE1 
(Figure 9A). Similar results were also obtained for another pair of cancer (U2OS) and non-
cancer cells (Fibroblasts) (Figure 9B). These data suggest that MLCK is less active in cancer 
cells compared to non-cancer cells.  
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Figure 9. MLCK activity is inhibited in cancer cells.  
(A) MLCK activity was compared between asynchronous non-cancer cells (RPE1) and cancer cells 
(UPCI:SCC103) by the in vitro kinase assay. Immunoblot on the left indicates the amount of 
immunoprecipitated MLCK used in the kinase assay. Immunoblots in this and all the subsequent 
experiments were also quantified using image-processing program Image J and minor adjustments were 
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given to the kinase assay values to account for any differences in the immunoprecipitation efficiencies. (B) 
MLCK activity was compared between another pair of non-cancer cells (Fibroblasts) and cancer cells 
(U2OS).  
 
However, MLCK activity also differs during the cell cycle. It is lower during early 
mitosis but increases almost two-fold during anaphase and cytokinesis. The above-mentioned 
inhibition of MLCK in cancer cells was observed in unsynchronized cell populations. As cancer 
cells typically have higher mitotic indices, we wanted to rule of the possibility of the observed 
MLCK activity difference being a result of cell cycle differences. Therefore, I compared MLCK 
activity in cell cycle synchronized non-cancer and cancer cells. Again, RPE1 and UPCI:SCC103 
were chosen as a representative non-cancer and cancer cell lines respectively, for the reasons 
described previously. Cells were synchronized in mitosis by nocodazole and in S-phase by a 
double thymidine block. In both instances, MLCK activity remained lower in cancer cells 
compared to non-cancer cells (Figure 10A and Figure 10B). Taken together, these data support 
our hypothesis that MLCK is inhibited for its kinase activity in cancer cells. In summary, MLCK 
is inhibited at two levels in cancer cells; it is expressed at lower levels and is also enzymatically 
less active.  
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Figure 10. MLCK activity is inhibited in cancer cells independent of the cell cycle differences 
between non-cancer and cancer cells.  
(A) MLCK activity was compared in vitro between RPE1 and UPCI:SCC103 cells after arrest in S-
phase by a double thymidine block. Left panel shows immunoprecipitation of MLCK from the indicated cell 
lines used in this assay. (B) MLCK activity was compared in vitro between RPE1 and UPCI:SCC103 cells 
after arrest in mitosis by nocodazole. Left panel indicates immunoprecipitation of MLCK from the indicated 
cell lines.  
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2.3.3 MLCK inhibition is the cause of cytokinesis failure in cancer cells 
To test if the observed MLCK inhibition was indeed the cause of cytokinesis failure, I examined 
the frequency of binucleation as an indicator of cytokinesis failure, after expression of a 
constitutively active MLCK construct in cancer cells. Constitutively active MLCK lacks C-
terminal amino acids 1745-1914 that encode an autoinhibitory domain, making the mutant 
MLCK constitutively active (Wadgaonkar et al., 2003). A kinase dead MLCK mutant that 
contains a deletion of an ATP binding site was used as a control (Wadgaonkar et al., 2003). 
Expression of both the mutant constructs was confirmed by immunoblotting (Figure 11A and 
Figure 11B).  
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Figure 11. Expression of a constitutively active and a kinase dead MLCK construct is confirmed by 
immunoblotting.  
(A) UPCI:SCC103 cells were transiently transfected with a V5 tagged constitutively active MLCK 
construct that contains a deletion of an autoinhibitory domain consisting of amino acids 1745-1914. 
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Immunoblots were probed using anti-MLCK antibody (left panel) and anti-V5 antibody (right panel). Only 
endogenous MLCK is seen in untreated cells, whereas along with endogenous MLCK, shorter fragments of 
the long and the short isoform, corresponding to the above-mentioned deletion are detected in cells 
transfected with a constitutively active MLCK. Both the shorter fragments are also detected with anti-V5 
antibody confirming their expression from the mutant plasmid. (B) UPCI:SCC103 cells were transiently 
transfected with a kinase dead MLCK construct that contains a 27 amino acid deletion of the ATP binding 
site. It is difficult to detect a change in 27 amino acids as a shift in the molecular weight of the long and the 
short isoforms. However, an increase in the protein levels of both the isoforms suggests successful expression 
of the mutant construct.  
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         Expression of a constitutively active MLCK construct, but not a kinase dead construct 
resulted in a significant decrease in the frequency of cytokinesis failure after two rounds of 
transfection in all the cancer cell lines tested (Figure 12) (p < 0.05 for all the cancer cell lines 
tested). These results suggest that inhibition of MLCK is a cause of cytokinesis failure in the 
tested cancer cell lines.  
 
Figure 12. MLCK inhibition is a cause of cytokinesis failure in cancer cells.  
Binucleation frequency was measured in the indicated cancer cell lines that were either untreated or 
were transfected with a kinase dead or a constitutively active MLCK constructs. In this and all the 
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subsequent experiments, binucleation frequency was determined by DAPI staining and epifluorescence 
microscopy (n=500-1000 cells for each experiment). Standard deviation between three independent 
experiments is shown as error bars. p value is calculated using a Student’s-t test and p<0.05 indicates a 
statistically significant difference.   
2.4 OVER-EXPRESSION OF AURORA B KINASE IS THE CAUSE OF MLCK 
INHIBITION AND CYTOKINESIS FAILURE 
After identifying MLCK inhibition as a cause of cytokinesis failure in cancer cells, our next goal 
was to identify the cause of MLCK inhibition. Differentially phosphorylated serine residues in 
MLCK are the consensus sites for Aurora B kinase phosphorylation. Furthermore, Aurora B can 
phosphorylate MLCK in vitro, but the consequences of this phosphorylation are not known. 
Considering the essential role of Aurora B during cytokinesis, well documented over-expression 
of Aurora B in a variety of tumor tissues and the tumorigenic potential of Aurora B over-
expression, I hypothesized that Aurora B kinase is an inhibitor of MLCK and over-expression of 
Aurora B is the cause of cytokinesis failure in cancer cells. I tested this hypothesis by three 
different approaches. Firstly, MLCK activity was measured in vitro in the absence and the 
presence of purified Aurora B. Secondly, Aurora B was over-expressed in non-cancer cells to 
test if it was sufficient to inhibit MLCK and cause cytokinesis failure. And thirdly, Aurora B 
protein levels were reduced in cancer cells to test if it could increase MLCK activity and reverse 
cytokinesis failure of cancer cells.  
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2.4.1 Aurora B can inhibit MLCK in vitro  
To test if Aurora B kinase was indeed an inhibitor of MLCK, I examined MLCK activity after 
addition of purified Aurora B kinase to an in vitro MLCK assay. Consistent with our hypothesis, 
addition of purified Aurora B resulted in a significant decrease in MLCK activity and suggested 
that MLCK could be inhibited directly by Aurora B (Figure 13). 
 
 
 
 
 
Figure 13. Aurora B inhibits MLCK in vitro.  
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MLCK was immunoprecipitated from RPE1 cells and in vitro MLCK activity was determined in the 
presence (+ArB) and the absence (-ArB) of added Aurora B. Immunoblot indicates MLCK 
immunoprecipitation used for two reactions. Standard deviation is shown as error bars that are present for 
all the data points. p value was calculated using a t-test for independent samples.  
2.4.2 Aurora B over-expression in non-cancer cells recapitulates MLCK inhibition in 
cancer cells  
To validate in vitro inhibition of MLCK by Aurora B in cultured cells, Aurora B kinase was 
over-expressed in a non-cancer cell line Human foreskin fibroblasts immortalized by expression 
of human telomerase reverse transcriptase (hTERT) known as HFF-hTERT. Considering the 
elimination of tetraploid cells in a p53 dependent manner, Aurora B was stably over-expressed 
on a WT and a p53 null background. Hereafter these cells will be named as follows: HFF+vector 
refers to HFF-hTERT expressing empty vector alone. HFF+ArB refers to HFF-hTERT stably 
over-expressing Aurora B on WT p53 background. HFFshp53 refers to HFF-hTERT with a 
stable shRNA mediated knock-down of p53 and HFFshp53+ArB refers to HFF-hTERT with a 
stable knock-down of p53 and stable over-expression of Aurora B. Aurora B over-expression 
was confirmed in the indicated cell lines by immunoblotting (Figure 14).  
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Figure 14. Aurora B over-expression in non-cancer cells is confirmed by immunoblotting.  
Aurora B protein levels in non-cancer cell line HFF-hTERT, stably transfected with the indicated 
plasmids were determined by immunoblotting. Actin was used a loading control. 
 
I first examined the protein levels of MLCK in all the above-mentioned cell lines. 
Interestingly, MLCK was expressed at lower levels only in HFFshp53+ArB cell line, indicating 
that down-regulation of MLCK expression can be recapitulated by over-expression of Aurora B 
in non-cancer cells (Figure 15A). 
To determine if Aurora B could inhibit MLCK activity, I compared the in vitro activity of 
MLCK immunopurified from HFFshp53 control and HFFshp53+ArB cells. Consistent with the 
MLCK enzymatic inhibition observed in cancer cells, MLCK immunopurified from Aurora B 
over-expressing HFF cells was less active compared to control cells (Figure 15B). Together, 
these data suggests that Aurora B over-expression in non-cancer cells is sufficient to down-
regulate MLCK expression and activity.  
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Figure 15. Over-expression of Aurora B in non-cancer cells recapitulates MLCK defects of cancer 
cells.  
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(A) MLCK expression was compared between HFF-hTERT cells with a stable over-expression of 
empty vector control (HFF+vector), over-expression of Aurora B (HFF+ArB), stable knock-down of p53 
(HFFshp53) and knock-down of p53 plus over-expression of Aurora B (HFFshp53+ArB). L and S represent 
the long and the short isoforms of MLCK respectively. Actin was used as a loading control. (B) MLCK 
activity is compared between HFFshp53 and HFFshp53+ArB cell line by in vitro kinase assay. Immunoblot in 
(B) indicates immunoprecipitation of MLCK from the indicated cell lines.   
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2.4.3 Aurora B over-expressing cells fail in cytokinesis as a result of MLCK inhibition 
and deficient MLC phosphorylation 
Over-expression of Aurora B is a known cause of tetraploidy (Tatsuka et al., 1998; Terada et al., 
1998). The above-mentioned data suggest that Aurora B over-expression in non-cancer cells 
results in MLCK inhibition. MLC is the only known substrate of MLCK and we have 
demonstrated that MLCK inhibition and deficient MLC phosphorylation are the causes of 
cytokinesis failure. Based on these data, I hypothesized that Aurora B over-expressing cells fail 
at cytokinesis as a result of MLCK inhibition and the resultant deficient MLC phosphorylation. 
In order to test this hypothesis, I firstly confirmed if HFF-hTERT cells over-expressing Aurora B 
fail in cytokinesis, as has been observed for other cell lines used in previously published studies. 
In agreement with the published literature, I observed an increase in the frequency of 
binucleation or cytokinesis failure in Aurora B over-expressing HFF cells. Consistent with the 
role of p53 in limiting the survival of tetraploid cells and observed MLCK down-regulation, an 
increase in the binucleation frequency was observed only in the cell line over-expressing Aurora 
B in a p53 null background (Figure 16A). Next, to test if the observed cytokinesis failure was a 
result of MLCK inhibition and deficient MLC phosphorylation, I examined binucleation 
frequency in HFFshp53+ArB cell line after transient transfection of a phosphomimetic MLC 
(GFP-MLCDD) and a constitutively active MLCK construct. In contrast to empty GFP vector or 
kinase dead MLCK controls, expression of phosphomimetic MLC or constitutively active 
MLCK resulted in a significant decrease in the binucleation frequency in HFFshp53+Aurora B 
cell line (Figure 16B). 
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Figure 16. Aurora-B induced cytokinesis failure is mediated through MLCK inhibition and a 
reduction in MLC phosphorylation.  
(A) Binucleation frequency was determined in the indicated HFF cell lines. (B) Binucleation 
frequency was measured in HFFhsp53+ArB cell line after a transient transfection of a kinase dead MLCK or 
a constitutively active MLCK construct and an empty GFP vector control or a phosphomimetic GFP (GFP-
MLCDD) construct. 
 
In summary so far, we have demonstrated that Aurora B can inhibit MLCK directly. In 
cultured non-cancer cells, over-expression of Aurora B is sufficient to down-regulate protein 
levels and kinase activity of MLCK and Aurora B over-expressing non-cancer cells fail in 
cytokinesis because of MLCK inhibition and deficient MLC phosphorylation.  
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2.5 AURORA B OVER-EXPRESSION IS THE CAUSE OF CYTOKINESIS FAILURE 
IN CANCER CELLS   
2.5.1 Cancer cells over-express Aurora B  
My next goal was to investigate if Aurora B over-expression was indeed the cause of observed 
MLCK inhibition and cytokinesis failure in cancer cells. As demonstrated by many studies, 
Aurora B over-expression is one of the common characteristics of a variety of tumor tissues 
(Chieffi et al., 2006; Lin et al., 2006; Qi et al., 2007; Sorrentino et al., 2005). Therefore I wanted 
to confirm if it was true for the cancer cell lines used in this study as well. I firstly compared 
Aurora B protein levels between unsynchronized non-cancer and cancer cell lines by 
immunoblotting. Consistent with the previous published literature, Aurora B was expressed at 
higher levels in all the cancer cell lines tested (Figure 17A). However, Aurora B protein levels 
vary during cell cycle. Considering its multi-dimensional role during mitosis, Aurora B levels 
peak at G2-M transition (Bischoff et al., 1998). As cancer cells have higher mitotic indices, it is 
often debated whether elevated Aurora B levels seen in unsynchronized cancer cells are merely a 
reflection of increased mitotic indices and not a real pathological feature of cancer cell 
populations (Nikiforov, 2005). To address this concern, I compared Aurora B protein levels in 
three different pairs of non-cancer and cancer cells after synchronizing them in mitosis with 
nocodazole. It was essential to treat different cell lines with different concentrations of 
nocodazole as described in the Methods section (Chapter 4, section 4.7.2), to achieve comparable 
mitotic indices. Comparison of matched pair of non-cancer and cancer cell lines demonstrated 
that cancer cells had markedly higher Aurora B protein levels even at similar mitotic frequencies. 
Induction of higher frequency of mitotic indices such as in RPE1 cells, minimized the difference 
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in Aurora B levels as expected, but it is important to note that unsynchronized RPE1 cells still 
expressed Aurora B at lower levels compared to other cancer cells (Figure 17B).    
 
Figure 17. Aurora B is over-expressed in cancer cells independent of the differences in mitotic 
indices.  
(A) Aurora B protein levels were compared by immunoblotting between asynchronous non-cancer 
and cancer cells. Actin was used as a loading control. (B) Aurora B expression was compared between three 
different pairs of non-cancer and cancer cells after achieving comparable mitotic indices from mitotic arrest 
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with nocodazole. OKF-hTERT, HFF-hTERT and RPE1 are non-cancer cells whereas UPCI:SCC103, U2OS 
and A549 are cancer cells.  MI represents mitotic indices.  
2.5.2 Over-expression of Aurora B kinase is the cause of cytokinesis failure in cancer cells  
Aurora B over-expression results in cytokinesis failure and tetraploidization (Tatsuka et al., 
1998; Terada et al., 1998). In contrast, complete depletion of Aurora B levels either by siRNA or 
inhibition of its kinase activity by chemical inhibitors also results in the formation of tetraploid 
or polyploidy cells (Ditchfield et al., 2003; Tsuno et al., 2007). Therefore it appears that 
‘optimal’ levels of Aurora B are required for successful cytokinesis such that imbalance in 
Aurora B levels on either the higher or lower side of the ‘optimal’ level causes cytokinesis 
failure. To test this possibility, I counted the frequency of binucleation after complete or partial 
knock-down of Aurora B using siRNA. To rule out the possibility of any off-target effects of 
RNAi mediated silencing, two different siRNAs were used to knock-down Aurora B.  siRNA # 1 
targeted the N-terminal region of Aurora B mRNA and siRNA # 2 targeted the C-terminal 
region. Aurora B has a very high sequence similarity with Aurora A. Aurora A is a known 
oncogene and mis-regulation of Aurora A can also cause cytokinesis defects (Marumoto et al., 
2003). Considering the high sequence homology between Aurora B and Aurora A, non-specific 
targeting of Aurora A mRNA by Aurora B siRNA is a common concern. Therefore, we 
examined Aurora A protein levels after Aurora B knock-down and found them to be unaltered, 
thus ruling out the possibility of non-specific knock-down of Aurora A by Aurora B siRNA 
(Figure 18).  
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Figure 18. Aurora B siRNA does not have an off-target affect on Aurora A mRNA.  
              Aurora A kinase protein levels were measured after transfection of U2OS cells with 167 and 50 
nanomolar concentration of Aurora B siRNA for 24 hours respectively. Actin was used as a loading control.  
 
After confirming the specificity of Aurora B siRNAs, I completely knocked-down Aurora 
B protein levels in cancer cell line U2OS using both siRNAs. To achieve complete knock-down 
of Aurora B, cells were treated cells with 167 nanomolar of siRNA for 48 and 24 hours. 
Consistent with the published literature, a complete knock-down of Aurora B resulted in a 
significant increase in the binucleation frequency (Figure 19A leftmost and middle panels). As 
expected, 48 hours of knock-down resulted in a greater increase in the binucleation compared to 
24 hours of complete knock-down. To test our hypothesis that optimal levels of Aurora B are 
required for cytokinesis, I then partially knocked-down Aurora B protein levels in U2OS cells by 
treating them with 50 nanomolar of siRNA for 24 hours. Consistent with our prediction, a partial 
knock-down of Aurora B resulted in a significant decrease in the binucleation frequency (Figure 
19A, rightmost panel). Similar results were obtained with the use of siRNA # 2 as well (Figure 
19B)  
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Figure 19. A partial knock down of Aurora B reduces cytokinesis failure in cancer cells U2OS.  
(A) Binucleation frequency was compared between control siRNA (siC) and Aurora B siRNA #1 
(siArB) treated U2OS cells. Leftmost and middle panel show the data obtained from 48 and 24 hours of 
complete knock-down of Aurora B respectively, achieved with the use of 167 nanomolar of siRNA. Rightmost 
panel shows the data obtained from 24 hours of a partial knock-down of Aurora B achieved with 50 
nanomolar of Aurora B siRNA. Bottom panels demonstrate immunoblots of Aurora B protein levels after 
respective knock-downs. (B) Similar analysis as in (A) was performed in U2OS cells using a second non-
overlapping siRNA against Aurora B (siRNA # 2)  
 
This hypothesis was also confirmed using oral squamous cell carcinoma cell line 
UPCI:SCC70 (Figure 20A and Figure 20B).  
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Figure 20. Cytokinesis failure is reduced after a partial knock-down of Aurora B protein levels in 
cancer cells UPCI:SCC70.  
(A) Binucleation frequency was compared between control siRNA (siC) and Aurora B siRNA # 1 
(siArB) treated oral squamous cell carcinoma cells UPCI:SCC70. Data obtained after 48 and 24 hours of 
complete knock-down of Aurora B is indicated in the leftmost and the middle panel respectively. Data 
obtained after 24 hours of a partial knock-down of Aurora B protein levels is demonstrated in the rightmost 
panel. Bottom panels are the immunoblots of Aurora B protein levels in the indicated knock-downs. (B) 
Similar analysis as in (A) was performed using siRNA # 2 in UPCI:SCC70 cells.  
 
Taken together, these data tells us that Aurora B over-expression is a cause of cytokinesis 
failure in cancer cells and a partial knock-down of Aurora B protein levels reduces the frequency 
of cytokinesis failure, supporting the idea that optimal levels of Aurora B are required for 
successful cytokinesis. 
2.5.3 A partial knock-down of Aurora B in cancer cells increases MLCK activity and 
expression  
The data presented so far suggests that Aurora B over-expression is the cause of cytokinesis 
failure in cancer cells. We hypothesize that the observed cytokinesis failure in Aurora B over-
expressing cancer cells occurs due to inhibition of MLCK. To validate this hypothesis, we 
examined MLCK activity in U2OS cancer cells after knock-down of Aurora B. As we observed a 
reduction in cytokinesis failure in cancer cells after knocking-down Aurora B to a partial levels, 
we measured MLCK activity at the similar level of Aurora B knock-down, achieved by treating 
cells with 50 nanomolar of siRNA for 24 hours. Corresponding to a decrease in the binucleation 
frequency, an increase in MLCK activity was observed after a partial knock-down of Aurora B 
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(Figure 21A). Similarly, MLCK expression also increased after a partial knock-down of Aurora 
B (Figure 21B). Thus both the parameters of MLCK inhibition in cancer cells i.e. decreased 
expression and reduced kinase activity were reversed upon decreasing Aurora B protein levels. 
These data provided further evidence that Aurora B over-expression results in cytokinesis failure 
because of the inhibition of MLCK. 
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Figure 21. A partial knock-down of Aurora B with siRNA # 1 increases MLCK activity and protein 
levels in cancer cells U2OS.  
MLCK in vitro activity (A) and MLCK expression (C) was compared between control siRNA (siC) 
and Aurora B siRNA #1 (siArB) treated U2OS cells. Left panel of immunoblot in (A) demonstrates 
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immunoprecipitation of MLCK from siC and siArB treated U2OS cells that were used in the kinase assay. 
Immunoblot in (B) demonstrates a partial knock-down of Aurora B observed in this experiment. Actin was 
used as a loading control. For some data points errors bars are very small and therefore not visible.  
 
Similar results were obtained using a second siRNA against Aurora B in U2OS cells (Figure 22 
A and Figure 22B) and a different cancer cell line UPCI:SCC70 (Figure 23A). In summary, these 
data confirms that Aurora B over-expression is a cause of MLCK inhibition and resultant 
cytokinesis failure in cancer cells 
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Figure 22. A partial knock-down of Aurora B with siRNA # 2 also increases MLCK activity and 
expression in U2OS cells.  
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MLCK in vitro activity (A) and MLCK protein levels (B) were measured in control siRNA (siC) and 
Aurora B siRNA # 2 (siArB) treated U2OS cells. Immunoblot in (A) demonstrates MLCK 
immunoprecipitation from the indicated cells.  
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Figure 23. A partial knock-down of Aurora B increases MLCK activity and expression in cancer cells 
UPCI:SCC70.  
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MLCK in vitro activity (A) and MLCK expression (B) was measured in a second cancer cell line 
UPCI:SCC70 after transfection of a control siRNA (siC) or Aurora B siRNA (siArB). Immunoblots in (A) 
show MLCK immunoprecipitation used in the respective reactions.  
2.5.4 Aurora C kinase also phosphorylates MLCK and increases MLCK activity 
Aurora kinase family has three members, Aurora A, Aurora B and Aurora C kinase. Out of the 
three members, functions of Aurora C are probably the least well understood. Aurora C was 
indentified by a homology search for kinases homologous with Aurora B kinase. It was shown to 
be more closely related to Aurora B kinase with 83% of sequence homology between Aurora B 
and Aurora C kinase domains (Kimura et al., 1999). It is predominantly expressed in testis and is 
required for spermatogenesis (Kimmins et al., 2007). Adults also express Aurora C in other 
tissues such as placenta, ovary and liver but at very low levels (Yan et al., 2005). Interestingly, 
Aurora C gene AIK3 is mapped on chromosome 19q13.43, a region that is commonly rearranged 
or deleted in cancer cells (Kimura et al., 1999), demanding further investigations into functions 
of Aurora C. Consistent with the sequence homology between Aurora B and Aurora C, Aurora C 
also demonstrates functional redundancy with Aurora B.  Similar to Aurora B, Aurora C interacts 
with CPC components INCENP and survivin and localizes to the spindle midzone during 
cytokinesis (Sasai et al., 2004; Yan et al., 2005). Kinase dead mutant of Aurora C as well as 
siRNA mediated knock-down of Aurora C results in cytokinesis failure and multinucleation, 
further demonstrating its functional similarity with Aurora B (Sasai et al., 2004; Yan et al., 2005; 
Yang et al., 2010). Aurora C appears to replace Aurora B for normal CPC functioning in the pre-
implantation stage of embryogenesis (Fernandez-Miranda et al., 2011). Interestingly, in cultured 
cells, Aurora C can complement Aurora B function and can rescue multinucleation phenotype of 
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Aurora B inhibition (Sasai et al., 2004). These data demonstrate that Aurora C functions 
redundantly with Aurora B. Therefore I decided to investigate if Aurora C is also a regulator of 
MLCK activity. 
Firstly, we examined if MLCK was a substrate of Aurora C kinase. To test this 
possibility, I performed in vitro phosphorylation assay. Purified Aurora C was added to the 
kinase assay containing radiolabeled ATP and immunoprecipitated MLCK as a substrate. After 
30 minutes of incubation, the reaction was run on a gel and imaged using phosphorimager to 
detect any possible phosphorylation of MLCK. As MLCK autophosphorylates (Tokui et al., 
1995), a phosphorylation band  corresponding to the long isoform of MLCK was detected even 
in the absence of added Aurora C and was absent after the addition of MLCK specific inhibitor 
ML-7. Phosphorylation of the long isoform was detected even in the presence of ML-7 after 
addition of purified Aurora C indicating that MCLK is an Aurora B substrate. A phosphorylation 
band corresponding to the autophosphorylation of Aurora C was detected at the correct 
molecular weight ensuring that added Aurora C was active. These results suggest that MLCK is 
indeed a substrate of Aurora C kinase in vitro and Aurora C specifically phosphorylates the long 
isoform of MLCK (Figure 24A). To further investigate the effects of Aurora C phosphorylation 
on MLCK activity, MLCK activity assay was performed in the presence of purified Aurora C 
kinase. Surprisingly, in contrast to Aurora B kinase, addition of Aurora C kinase resulted in an 
increase in MLCK activity (Figure 24B).  
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Figure 24. Aurora C kinase phosphorylates MLCK and increases its activity.  
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(A) MLCK phosphorylation assay was performed in the presence of MLCK alone, in the presence of 
MLCK specific inhibitor ML-7 (used to inhibit MLCK autophosphorylation) and after addition of purified 
Aurora C plus ML-7.  (B) MLCK activity was measured in vitro in the presence (+ArC) and the absence  
(-ArC) of purified Aurora C kinase. Immunoblot in (B) indicates immunoprecipitaion of MLCK used in the 
reaction.  
 
Thus, even though MLCK is a substrate of Aurora C similar to Aurora B, Aurora C 
appears to activate MLCK in contrast to inhibitory effect of Aurora B. Consistent with the 
inhibition of MLCK in cancer cells and activation of MLCK by Aurora C kinase, I observed 
lower expression of Aurora C in UPCI:SCC103 cancer cells compared to RPE1 non-cancer cells 
(Figure 25 ). Similar results of the lower levels of Aurora C transcripts have been reported in a 
few other cancer cell lines (Lin et al., 2006). However, the consequences and significance of 
MLCK activation by Aurora C is not clearly understood at this point and needs further 
investigation.    
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Figure 25. Aurora C is expressed at lower levels in cancer cells UPCI:SCC103.  
Aurora C protein levels were compared between non-cancer cells RPE1 and oral squamous cell 
carcinoma cells UPCI:SCC103. Actin was used as a loading control. 
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2.6 CONCLUSIONS AND DISCUSSION  
My results uncover for the fist time, a molecular pathway that leads to cytokinesis failure in 
cancer cells. The pathway enumerated by our data is shown below: 
Aurora B over-expression → MLCK inhibition → deficient MLC phosphorylation → 
cytokinesis failure 
We have taken a bottom up approach to uncover the causes of cytokinesis failure. We 
have demonstrated that cancer cells are deficient in MLC phosphorylation and deficient MLC 
phosphorylation is the cause of cytokinesis failure. MLCK, an upstream regulator of MLC 
phosphorylation, is expressed at lower levels in cancer cells and shows reduced activity and this 
inhibition plays a causal role in cytokinesis failure. 
Further, Ie have demonstrated that Aurora B over-expression is the cause of MLCK 
inhibition and cytokinesis failure. MLCK activity is inhibited directly in vitro by addition of 
purified Aurora B kinase. MLCK inhibition observed in cancer cells can be reproduced in non-
cancer cells through over-expression of Aurora B. And lastly, cancer cell inhibition of MLCK 
expression and activity and the resultant cytokinesis failure can be reduced by partially 
knocking-down Aurora B. Taken together, these data establish a clear mechanistic link between 
Aurora B over-expression and cytokinesis defects, both commonly observed characteristics of 
tumor cells.  
I believe these results are relevant for the process of tumorigenesis in vivo. Isolation of 
tetraploid mouse mammary epithelial cells, made tetraploid by cytokinesis failure alone is 
sufficient to stimulate tumor formation (Fujiwara et al., 2005). Interestingly, injection of Aurora 
B over-expressing tetraploid murine epithelial cells form nearly two-fold larger tumors compared 
to diploid Aurora B over-expressing cells, suggesting that cytokinesis failure is critical for the 
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tumor forming ability of Aurora B over-expression (Nguyen et al., 2009). Our data suggest that 
MLCK inhibition and deficient MLC phosphorylation play a central role in mediating Aurora B 
induced tumorigenesis, a model that can be explored further in animal studies.  
MLCK is phosphorylated differently during interphase and mitosis (Poperechnaya et al., 
2000). In metaphase MLCK is phosphorylated primarily within the IgG domain, at additional 
unique sites than those observed in interphase. Considering the lower activity of MLCK during 
metaphase, these phosphorylation sites appear to be predominantly inhibitory. Our results and 
the previous work from the Bresnick lab identify Aurora B as the upstream kinase responsible 
for inhibition of MLCK. During anaphase, MLCK activity increases back allowing cytokinesis to 
proceed. However, as cancer cells over-express Aurora B, metaphase inhibition of MLCK 
appears to continue during anaphase resulting in persistent MLCK inhibition and cytokinesis 
failure.  
[R/K] [X] [T/S] [I/L/V] has been identified as the consensus Aurora B phosphorylation 
site (Cheeseman et al., 2002). Sequence analysis of long MLCK reveals 12 potential Aurora B 
phosphorylation sites, eight of which are located within the IgG domain (Dulyaninova and 
Bresnick, 2004). In the future, phosphopeptide mapping and mutagenesis studies can identify the 
actual sites that are phosphorylated and the effect of these phosphorylation events on MLCK 
activity. It would also be interesting to investigate potential differences if any, in the 
phosphorylation of these putative sites in cancer and non-cancer cells.  
Lower expression of MLCK has been reported previously in some of the tumor types 
(Lee et al., 2008; Leveille et al., 2009). However, the mechanism of MLCK down-regulation has 
never been shown. Consistent with other reports, our results confirm lower abundance of MLCK 
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protein in a variety of cancer cells. As both the expression and the activity of MLCK appear to 
be regulated by Aurora B, it is an interesting possibility that they are inter-dependent.  
Aurora B phosphorylates the long isoform of MLCK in vitro but not the short isoform. 
(Dulyaninova and Bresnick, 2004). Preferential localization of the long isoform to the cleavage 
furrow makes it a more relevant Aurora B target during cytokinesis. However, MLCK antibody 
used in this study binds both the isoforms and the kinase assays measure the combined activity of 
both the long and the short isoforms and do not distinguish between the effects of Aurora B on 
the two isoforms separately. It is more likely that the observed changes are entirely due to the 
phosphorylation of the long isoform. However, the possible effects of Aurora B mis-regulation 
on the activity of the short isoform cannot be ruled out at this stage. 
While I emphasize the role of MLCK during cytokinesis, in vitro kinase assay performed 
with S-phase arrested cells demonstrates inhibition of MLCK even in the interphase of cancer 
cells. Cells can divide by the traction forces acting at the periphery, independent of the cleavage 
furrow (Kanada et al., 2005). As MLCK regulates contractile processed associated with cell 
adhesion and motility (Katoh et al., 2001), changes associated with the cell motility outside of 
the cleavage furrow can also influence cytokinesis outcome in tumor cells. Additionally, 
interphase inhibition of MLCK can influence cell motility relevant to the metastatic potential of 
the cancer cells. So far, all the known functions of Aurora B involve mitotic processes. But in 
one example of T lymphocytes, Aurora B is found to be present in all the stages of cell cycle and 
is required for the G1 to S transition (Song et al., 2007). Thus it is possible that interphase 
inhibition of MLCK is also mediated by Aurora B kinase.  
My data also identify Aurora C as an additional regulator of MLCK activity. Aurora C 
binds to CPC components similar to Aurora B and rescues Aurora B depletion phenotypes. Thus, 
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Aurora C appears to function redundantly with Aurora B. Interestingly, my data demonstrates 
that unlike Aurora B, Aurora C activates MLCK. Both Aurora B and Aurora C mRNA levels are 
elevated at G2/M stage of cell cycle. However, Aurora B levels peak and drop ahead of Aurora C 
during mitosis. Aurora B levels taper at the end of M phase but Aurora C persists even after exit 
of M phase (Sasai et al., 2004). This cell cycle distribution of Aurora B and C levels and their 
opposing effect on MLCK activity correlate very well with the observed inhibition of MLCK 
during metaphase and activation during anaphase and these apparently antagonistic effects of 
Aurora B and C appear to be important for the temporal regulation of MLCK during cytokinesis. 
There are some conflicting results about Aurora C levels in tumor tissues. Some studies report 
elevated levels whereas others report decreased levels of Aurora C transcripts in tumor tissues 
(Lin et al., 2006; Sasai et al., 2004). Although I observed reduced Aurora C protein levels and 
reduced MCLK activity in oral cancer cells, this observation needs to be validated in other 
cancer cell lines. 
In summary, my work identifies a novel mechanism of MLCK regulation by Aurora B 
and Aurora C kinase and provides insights into the causes of cytokinesis failure in cancer cells.  
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3.0  LINGERING CHROMATIN TRIGGERS CYTOKINESIS FAILURE 
3.1 INTRODUCTION  
Data presented in chapter 2 describes a novel pathway of cytokinesis failure mediated by Aurora 
B over-expression and the downstream MLCK and pMLC inhibition. As described in the 
introduction, cytokinesis failure is typically observed in only in a subset of cancer cells. As the 
conclusions presented in chapter 2 were based on population based studies, it was not possible to 
distinguish if the activation of this pathway and abortive cytokinesis occurred stochastically in 
some of the cells or if there was an underlying factor that specifically triggered this pathway in a 
certain population of the cells. 
Faithful cytokinesis requires tight coordination of chromosome segregation and cleavage 
furrow ingression. Under normal circumstances, two sets of chromosomes segregate away from 
the cleavage plane shortly after the onset of anaphases and the progression of cytokinesis in the 
presence of uncleared chromatin results in extensive DNA damage (Janssen et al., 2011). 
Therefore, cytokinesis completion needs to await complete clearance of the chromatin from the 
cleavage plane. Consistent with this idea, it has been demonstrated that lagging chromatin at the 
cleavage furrow results in abortive cytokinesis (Mullins and Biesele, 1977; Shi and King, 2005). 
However, the mechanism of lingering chromatin induced cytokinesis failure remains unknown. 
Based on our data, we hypothesize that the cells with lingering chromatin fail in cytokinesis by 
triggering MLCK and MLC phosphorylation inhibition pathway. In other words, we believe that 
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cytokinesis failure is not a stochastic process but occurs specifically in cells with lingering 
chromatin at the cleavage plane. 
More than a century ago, David Hansemann reported frequent occurrence of 
asymmetrical anaphases in epithelial cancers characterized by the presence of lagging 
chromosomes or the bridges formed by the sticky chromosomes (Hansemann, 1890; Hardy and 
Zacharias, 2005). Hansemann’s work was forgotten for many decades until the advances in 
cytogenetics established chromosome segregation defects as a very common characteristic of 
cancer cells. They occur in about one percent of the dividing somatic cells but at a much higher 
frequency in cancer cells, a possible explanation for the higher frequency of cytokinesis failure 
in cancer cells (Cimini et al., 2003; Gisselsson, 2008; Gisselsson et al., 2000; Saunders et al., 
2000). Chromosome segregation errors that can lead to the presence of lingering chromatin at the 
cleavage plane are primarily anaphase bridges and lagging chromosomes. Anaphase bridges and 
lagging chromosomes will be described individually in the following sections but will be 
referred together as lingering chromatin for the purposes of this study. 
3.1.1 Anaphase bridges 
Anaphase bridge can be defined as a continuous string of DNA connecting two main segregating 
masses of chromosomes at two anaphase poles. They can be further classified into chromatid or 
chromosome bridges (McClintock, 1941). Chromatid bridge is formed by the fusion of two sister 
chromatids before the separation of centromeres. This leads to the stretching of the 
intercentromeric DNA during anaphase resulting in the breakage of a chromatid segment at one 
or multiple locations. Similarly, if two chromosomes fuse together, they face a tug of war during 
anaphase resulting in DNA double strand breaks. Once the DNA ends are broken, they can be 
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ligated back or can fuse illegitimately with other chromosomes forming novel dicentric 
chromosomal structures. The resultant dicentric chromosome again undergoes a tug of war in the 
following mitosis resulting in the breakage-fusion-breakage cycle of anaphase bridges formation 
(McClintock, 1938, 1941).  
Any DNA damaging event that triggers DNA double strand breaks (DSB) can initiate the 
formation of anaphase bridges. Cells have evolved a variety of DNA damage repair pathways 
such as homologous recombination or non-homologous end joining to restore the original 
chromosomal structure after DSB (Kass and Jasin, 2010). However an inaccurate repair process 
can fuse non-identical chromosome ends together resulting in the formation of anaphase bridges 
(Pfeiffer et al., 2000). DSB and the resultant anaphase bridges can occur spontaneously during 
cellular processes or can be induced by exogenous agents such as ionizing radiation or IR 
(Hagen, 1994; Humphrey and Brinkley, 1969; Pfeiffer et al., 2000). Another common source of 
anaphase bridges is the shortening of telomeric TTAGGG repeats (Artandi et al., 2000; 
Gisselsson et al., 2001). Shortened telomeric ends, as observed in aging cells or in tumors, can be 
inappropriately treated as DSB leading to terminal fusion of two chromosomes or sister 
chromatids and initiation of breakage-fusion-breakage cycle (Gisselsson, 2005). Inactivation of 
p53 plays an important role in promoting breakage-fusion-breakage cycle after telomere 
shortening (Artandi et al., 2000).  
3.1.2 Lagging chromosomes 
Lagging chromosomes is a rather poorly defined term used to describe chromosomes that are left 
behind at the spindle equator during anaphase when the majority of the sister chromatids have 
moved away from each other towards the opposite spindle poles (Cimini et al., 2001; Cimini et 
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al., 1999). Lagging chromosomes are frequently observed in cancer cells and are recognized as 
an important source of aneuploidy and chromosomal instability (Reing et al., 2004; Saunders et 
al., 2000; Thompson and Compton, 2008).  
            Lagging chromosomes arise primarily from errors in kinetochore–microtubules 
attachments, specifically merotelic kinetochore-microtubule attachment (Cimini et al., 2001). 
When a single kinetochore attaches to microtubules emanating from both the poles, it faces the 
pulling forces in opposite direction causing it to lag behind.  Merotelic attachment are commonly 
observed in early mitosis even in normal tissues (Salmon et al., 2005). However, there are 
cellular mechanisms that prevent and correct merotelic attachments before the onset of anaphase 
and involve proteins that primarily regulate chromosome and kinetochore structures and the 
dynamics of microtubules at the kinetochore (Gregan et al., 2011). Centromerically located 
Aurora B kinase is at the centre of these corrective mechanisms. Aurora B is enriched at the 
merotelically attached chromosomes and corrects these erroneous attachments by altering the 
activity of kinetochore proteins such as the KMN network and microtubule depolymerizing 
proteins such as MCAK (Knowlton et al., 2006; Welburn et al., 2010). However, mechanisms 
correcting merotelic attachments can get overwhelmed if misaligned chromosomes occur at a 
very high frequency. For example, cells recovering from nocodazole treatment experience a very 
high frequency of merotely that is beyond the correction capacity of cells and hence they 
experience a very high frequency of lagging chromosomes (Cimini et al., 1999). Similarly, 
cancer cells experience a higher frequency of merotelic attachments, most commonly during the 
coalescence of extra centrosomes, and hence demonstrate higher frequency of lagging 
chromosomes (Ganem et al., 2009; Silkworth et al., 2009). Also, deficiencies in the corrective 
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mechanisms can further promote merotely and the occurrence of lagging chromosomes in cancer 
cells.  
3.1.3 Role of Aurora B kinase in coordinating cytokinesis with chromatin clearance from 
the cleavage plane  
How cytokinesis is coordinated with chromatin clearance to avoid DNA damage was a 
completely unanswered question until a recent discovery of the NoCut pathway, described for 
the first time in yeast Saccharomyces cerevisiae (Norden et al., 2006). The NoCut pathway 
ensures that cytokinesis proceeds only after all the chromosomes are moved away from the 
cleavage plane. Aurora B kinase Ipl1 is at the center of this pathway. In the presence of midzone 
defects, Ipl1 delays cytokinesis completion by recruiting anillin related protein Boi1 and Boi2 at 
the cleavage site to inhibit abscission. Later, similar pathway was also identified in mammalian 
cells with a conserved role for Aurora B (Steigemann et al., 2009). In the presence of 
unsegregated chromatin, mammalian Aurora B delays abscission by phosphorylating and 
stabilizing Mklp1at the intracellular canals.  
As Aurora B plays an essential role in coordinating chromatin clearance with cytokinesis 
timing, we hypothesize that Aurora B dependent MLCK and MLC inhibition pathway is 
activated in a response to lingering chromatin to prevent cytokinesis completion.   
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3.2 RESULTS  
3.2.1 Lingering chromatin interferes with cytokinesis  
To test the hypothesis of lingering chromatin interfering with cytokinesis by inhibition of MLCK 
and MLC phosphorylation, I first tested if cells indeed fail at cytokinesis in the presence of 
lingering chromatin by measuring the binucleation frequency after induction of chromosome 
segregation defects in HFFshp53 cells and the cancer cells U2OS with a treatment of 2.8-3 Gy of 
ionizing γ-radiation (IR). IR primarily causes DNA double strand breaks and results in the 
formation of anaphase bridges most likely due to delayed or incomplete repair of these breaks 
(Fenech et al., 2011; Hagen, 1994; Pfeiffer et al., 2000). Cells with WT p53 senesce in the 
presence of chromosome bridges. Therefore it was important to use p53 null HFF cell line to 
promote the formation of anaphase bridges (Artandi et al., 2000). As expected, cells treated with 
IR demonstrated an increase in the frequency of lingering chromatin (Figure 26A) and consistent 
with other studies, it resulted in cytokinesis failure as demonstrated by an increase in the 
frequency of binucleation (Figure 26B). It is important to note that even untreated cancer cells 
U2OS had a higher frequency of lingering chromatin and binucleation compared to untreated 
HFFshp53 cells. This observation was expected as cancer cells have higher frequency of 
segregation errors and cytokinesis failure.  
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Figure 26. Induction of lingering chromatin increases cytokinesis failure.  
(A) Percentage of cells with chromosome bridges and lagging chromosomes were measured in 
untreated cells (black bars) and cells treated with 2.8-3 Gy of ionizing γ-radiation (grey bars). (B) 
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Binucleation frequency was measured in untreated (black bars) or irradiated (grey bars) cells. Two bars on 
the left of each figure show the data from HFFshp53 cells while two bard on the right show the data from 
U2OS cells.  
3.2.2 Cells with lingering chromatin are deficient in phosphorylated MLC at the cleavage 
furrow  
My hypothesis predicts that lingering chromatin will interfere with actin-myosin contractile 
ability as a result of MLCK inhibition and deficiencies in MLC phosphorylation. MLCK 
activates MLC by predominantly phosphorylating Ser19 residue and to a lesser extent Thr18 
residue (Ikebe and Hartshorne, 1985). Therefore to test our hypothesis, I induced lingering 
chromatin in HFFshp53 and U2OS cells by treating them with IR and then examined the 
localization of Ser19 phosphorylated MLC (hereafter referred to as pMLC) at the cleavage 
furrow in the presence and absence of lingering chromatin. As shown in the representative 
examples, in the absence of lingering chromatin pMLC was robustly enriched at the cleavage 
furrow in approximately 80% of the anaphases of HFFshp53 cells (Figure 27A). However, in the 
presence of lingering chromatin pMLC enrichment was greatly diminished in almost 80% of the 
anaphases. Similar results were also observed for cancer cells U2OS (Figure 27B). These data 
suggest that lingering chromatin could interfere with actin-myosin contraction during cytokinesis 
by interfering with activating phosphorylation of MLC at the cleavage furrow.  
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Figure 27. MLC phosphorylation is deficient in the presence of lingering chromatin.  
(A) Representative images of the localization of MLC phosphorylated on Ser19 (pMLC) at the 
cleavage furrow in HFFshp53 cells in the presence (bottom panel) and the absence (top panel) of lingering 
chromatin (LC) are shown. Nuclei were stained with DAPI. Right panel indicates quantitation of pMLC 
localization in the presence (+LC) and the absence (-LC) of lingering chromatin (n=40 in two independent 
experiments each). (B) Representative images of pMLC localization at the cleavage furrow in the presence 
and the absence of lingering chromatin in U2OS cells are shown. Right panel indicates quantitation of pMLC 
localization (n=40 in two independent experiments). Insets in (A) and (B) are zoomed in images 
demonstrating the presence of lingering chromatin. 
 
           To further confirm these observations, I transfected a GFP tagged phosphomimetic MLC 
construct in cells prior to induction of bridges and examined its localization at the cleavage 
furrow. As demonstrated in (Figure 28), phosphomimetic MLC localized correctly at the 
cleavage furrow in the presence and absence of lingering chromatin. These data indicated that 
lingering chromatin specifically induced defects in MLC phosphorylation at Ser19 and Thr18. 
Taken together, these data suggests that lingering chromatin could interfere with actin-myosin 
contraction during cytokinesis by interfering with the activating phosphorylation of MLC at the 
cleavage furrow. 
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Figure 28 Phosphomimetic MLC localizes at the cleavage furrow even in the presence of lingering 
chromatin.  
Two representative images of the localization of phosphomimetic MLC (GFP-MLCDD) at the 
cleavage furrow in the presence of lingering chromatin (LC) in U2OS cells are shown. Nuclei were stained 
with DAPI. Insets indicate zoomed in images of lingering chromatin.  
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3.2.3 Cells with lingering chromatin exhibit excessive blebbing during cytokinesis  
While examining anaphases with lingering chromatin, I observed abnormal membrane 
protrusions indicative of blebbing. Blebs are protrusions of the cell membrane that result from 
actin-myosin contraction of the cortex (Charras, 2008). Even during normal cytokinesis, smaller 
blebs are often observed at the polar cortex. However, abnormal actin-myosin contraction can 
manifest in excessive blebbing activity that is often indicative of cytokinesis failure (Birkenfeld 
et al., 2007; Wu et al., 2010b). Interestingly, cells with dys-regulated MLCK activity are known 
to exhibit striking blebbing activity (Fishkind et al., 1991). Therefore, to further investigate the 
observed membrane protrusions, I co-immunostained cells for actin and pMLC. In the absence of 
lingering chromatin, I did not observe blebbing activity at the cell cortex (Figure 29A). However, 
in the presence of lingering chromatin, distinct membrane blebs were observed most commonly 
at the polar cortex (Figure 29B). These blebs were strongly positive for pMLC staining 
indicating abnormal MLC contractility at the polar cortex. These data suggest that anaphases 
with lingering chromatin demonstrate abnormal actin-myosin contractility in the form of 
blebbing, most likely preceding abortive cytokinesis. I would like to emphasize the detection of 
strong actin enrichment at the cleavage furrow even in the presence of lingering chromatin. Actin 
and myosin are recruited to the cleavage furrow independently. Therefore this actin enrichment 
indicates that cells with lingering chromatin are specifically deficient in MLC phosphorylation at 
the cleavage furrow and are not manifesting a general deficiency in contractile proteins. Note 
that deficient MLC phosphorylation alone should still lead to defects in actin-myosin contraction 
and cytokinesis failure. 
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Figure 29. Anaphases with lingering chromatin exhibit excessive blebbing.  
(A) A representative image of a normal anaphase with localization of actin and pMLC at the 
cleavage furrow in U2OS cells. (B) Two examples of Anaphases with lingering chromatin in U2OS cells, 
stained for actin and pMLC, are shown. Blebbing is observed as an abnormal protrusion of the cell cortex 
indicated by a white circle. Insets in (A) and (B) demonstrate zoomed in images of lingering chromatin.  
3.2.4 MLCK is deficient at the cleavage furrow in the presence of lingering chromatin in 
HFFshp53 cells  
MLCK is the key kinase that phosphorylates MLC at the cleavage furrow. My results presented 
in Chapter 2 demonstrate that MLCK inhibition is the primary cause of deficient MLC 
phosphorylation and cytokinesis failure. Therefore I wanted to test if cells with lingering 
chromatin are also deficient in MLCK localization at the cleavage furrow. To test this possibility, 
cells were immunostained for MLCK after treatment with IR. As expected, in HFFshp53 cells 
MLCK was typically enriched at the cleavage furrow in the absence of lingering chromatin but 
was enriched at the cleavage furrow in only ~ 60% of anaphases with lingering chromatin at the 
cleavage site (Figure 30).  
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Figure 30. MLCK is mis-localized from the cleavage furrow of HFFshp53 cells in the presence of 
lingering chromatin.  
MLCK localization at the cleavage furrow in the presence and the absence of lingering chromatin 
(LC) is shown. Inset is a zoomed in image demonstrating lingering chromatin. Right panel indicates 
quantitation of MLCK localization during anaphase in the presence (+LC) and the absence (-LC) of lingering 
chromatin.  
3.2.5 MLCK is not enriched at the cleavage furrow of cancer cells 
I performed similar analysis for MLCK enrichment at the cleavage furrow in the presence of 
lingering chromatin in cancer cells U2OS. Surprisingly, I failed to detect MLCK at the cleavage 
furrow in any dividing U2OS cells irrespective of the presence or absence of lingering chromatin 
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(Figure 31). To rule out the possibility of immunostaining artifacts, we modified the fixation and 
staining protocols, but consistently failed to detect MLCK at the cleavage furrow. To examine if 
these observations were true in other cancer cells lines, I compared MLCK localization in a panel 
of non-cancer and cancer cell lines. Consistent with the above observations, MLCK was enriched 
at the cleavage furrow of the tested non-cancer cells but was not detected at the cleavage furrow 
of the tested cancer cells (Figure 32). 
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Figure 31 MLCK is mis-localized from the cleavage furrow of all the dividing U2OS cells.  
Representative images of MLCK localization at the cleavage furrow in cancer cells U2OS in the 
absence (top panel) and the presence (bottom panel) of lingering chromatin at the cleavage plane are shown. 
Nuclei were stained with DAPI.  
.  
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Figure 32. MLCK is mis-localized from the cleavage furrow in all the tested cancer cells.  
(A) MLCK localization at the cleavage furrow of non-cancer cells RPE1, HFF-hTERT and OKF-
hTERT is shown. (B) MLCK staining in the anaphases of cancer cells UPCI:SCC103, HeLa, A549 and SK-
HEP1 is shown. Arrowheads denote mis-localization of MLCK from the cleavage furrow of cancer cells. 
Insets demonstrate corresponding DAPI stained nuclei.  
 
MLCK mis-localization from the cleavage furrow of cancer cells is not a result of a general 
defect of cytokinetic furrow formation as other protein like Aurora B localized correctly at the 
cleavage furrow of cancer cells during division (Figure 33). 
 114 
 
 
 
 
 
 
 115 
Figure 33. Aurora B is correctly localized at the cleavage furrow in cancer cells.  
Localization of Aurora B in non-cancer cells RPE1 and cancer cells UPCI:SCC103, A549, SK-HEP1 
and U2OS cells is shown. Arrow indicates the cleavage furrow. Insets demonstrate DAPI stained nuclei.  
 
                These results suggest that MLCK is mis-localized from the cleavage furrow of all the 
cancer cells. There can be several explanations for these observations. Firstly, I have 
demonstrated that MLCK is expressed at very low levels in cancer cells. Therefore low 
abundance of protein might prevent its detection at the cleavage furrow. However, MLCK was 
not detected at the cleavage furrow in cancer cells SK-HEP1 that expresses MLCK at relatively 
higher levels compared to other cancer cells. Therefore, low abundance of MLCK protein may 
not completely explain its absence from the cleavage furrow, but this possibility cannot be ruled 
out at this stage. Secondly, MLCK might be mis-localized as a result of more transient and often 
undetectable aberrant chromosome segregation events such as metrotelic or syntelic kinetochore-
microtubule attachments. And finally, as cancer cells over-express Aurora B, it might interfere 
with MLCK localization even in the absence of lingering chromatin.  
3.2.6 MLCK inhibition and deficient MLC phosphorylation is a cause of cytokinesis 
failure in cells with lingering chromatin 
Data presented in the above two sections suggest that cells with lingering chromatin are deficient 
in MLCK and activating MLC phosphorylation at the cleavage furrow. To test if these 
deficiencies were the sources of cytokinesis failure associated with lingering chromatin, I tested 
if phosphomimetic MLC or constitutively active MLCK could block lingering chromatin 
induced cytokinesis failure. Cells were transiently transfected with these constructs and the 
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binucleation frequency was determined after IR treatment. Compared to empty GFP vector or 
kinase dead MLCK controls, phosphomimetic MLC and constitutively active MLCK 
significantly reduced the frequency of binucleation after treatment with IR. These results were 
true in both HFFshp53 and U2OS cells (Figure 34A and Figure 34B respectively). Taken 
together, these data suggest that lingering chromatin interferes with MLCK activity and 
activating phosphorylation of MLC and restoring MLCK and pMLC largely prevents cytokinesis 
failure associated with lingering chromatin.  
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Figure 34. MLCK inhibition and deficient MLC phosphorylation is a cause of cytokinesis failure in 
cells with lingering chromatin.  
(A) Binucleation frequency was measured in untreated or irradiated HFFshp53 cells and cells 
irradiated and transfected with an empty GFP vector control or phosphomimetic MLC and a kinase dead or 
a constitutively active MLCK construct. (B) Binucleation frequency was measured in untreated or irradiated 
U2OS cells or cells irradiated and transfected with the indicated constructs. (n=500-100 in each of the three 
independent experiments) 
3.2.7 Aurora B is up-regulated in the presence of lingering chromatin 
Results from the above two sections indicate that MLCK inhibition and deficient MLC 
phosphorylation occur in the presence of lingering chromatin. I have also demonstrated that 
Aurora B over-expression is the upstream cause of MLCK inhibition. These two observations 
give rise to two possibilities. Either, lingering chromatin and Aurora B independently inhibit 
MLCK or the two events are linked together and indeed Aurora B over-expression is induced by 
lingering chromatin to cause downstream inhibition of MLCK. Interestingly, Aurora B is often 
over-expressed in cancer cells without changes in the gene copy number (Smith et al., 2005). It is 
required for correcting chromosome segregation errors such as merotely and also for 
coordinating cytokinesis with chromosome segregation. Taken together, these data make me 
favor the later possibility and we hypothesize that lingering chromatin is the underlying cause of 
Aurora B up-regulation and the resultant MLCK and pMLC inhibition. To test this hypothesis, 
we examined Aurora B protein levels after induction of lingering chromatin in HFFshp53 cells. 
We employed two different methods to induce lingering chromatin. Cells were treated with IR to 
cause DSB and induce anaphase bridges. Alternatively, cells were treated with monastrol to 
induce lagging chromosomes from spindle defects, as described previously (Janssen et al., 2011).  
 119 
Monastrol is an inhibitor of molecular motor Eg5, a motor required for bipolar spindle assembly 
(Mayer et al., 1999). Hence, cells treated with Eg5 inhibitor monastrol arrest in mitosis as a 
result of monopolar spindle formation. During the recovery from monastrol block, there is a 
significant increase in the frequency of lagging chromosomes probably as a result of increased 
incidence of merotely (Thompson and Compton, 2008). As per my prediction, induction of 
lingering chromatin, both by IR and by monastrol treatment led to an increase in Aurora B 
protein levels (Figure 35A). Exposure of cells to another DNA damaging agent UV-C that did 
not induce anaphase bridges or lagging chromosomes and did not increase Aurora B protein 
levels indicating that the increase in Aurora B levels was not a result of generalized DNA 
damage but a specific effect of lingering chromatin. Changes in Aurora B levels were not a result 
of changes in mitotic indices either as mitotic indices remained comparable after all the 
treatments (Figure 35B). These data supports our hypothesis that lingering chromatin indeed 
elevates Aurora B levels.  
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Figure 35. Aurora B protein levels are increased upon induction of lingering chromatin.  
(A) Aurora B protein levels were measured by immunoblotting after induction of lingering 
chromatin either by γ-radiation (right panel) or by release from monastrol block (left panel).  (B) Aurora B 
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protein levels were measured after exposure to DNA damaging agent UV-V. Bottom table in (A) and (B) show 
quantitation of mitotic indices and the frequency of lingering chromatin with respective treatments. 
Lingering chromatin percentage is calculated as the fraction of total anaphases with any chromatin not 
segregating with the main chromosome group. Actin and γ-tubulin were used as a loading control. 
3.2.8 Aurora B over-expression and MLCK inhibition is the cause of mis-localization of 
phosphorylated MLC in the presence of lingering chromatin 
As lingering chromatin induced Aurora B over-expression, we further wanted to test if this up-
regulation of Aurora B was responsible for MLC phosphorylation deficiencies in the presence of 
lingering chromatin. To test this possibility, we examined localization of pMLC at the cleavage 
furrow in the presence and absence of lingering chromatin after chemical inhibition of Aurora B 
kinase. A chemical inhibitor of Aurora B kinase named ZM447439 (ZM) was used for these 
purposes. ZM is a selective ATP competitive inhibitor of Aurora B kinase and was used at 2µM 
concentration for 45 minutes (Ditchfield et al., 2003). Aurora B inhibition was confirmed by 
diminished staining of a known Aurora B substrate, histone H3 phosphorylated on Ser10 (pH3) 
(Hsu et al., 2000). In untreated cells, pMLC was not enriched at the cleavage furrow in the 
presence of lingering chromatin (Figure 36). However, consistent with our hypothesis, pMLC 
enrichment returned to the cleavage furrow after inhibition of Aurora B. 68% of ZM treated cells 
showed enrichment of pMLC at the cleavage furrow in the presence of lingering chromatin in 
contrast to 16% of untreated cells. These results indicate that Aurora B activity is required for the 
inhibition of MLC phosphorylation in the presence of lingering chromatin.  
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Figure 36. MLC phosphorylation is restored in cells with lingering chromatin after inhibition of 
Aurora B.  
Localization of pMLC in the presence of lingering chromatin (LC) in U2OS cells was examined in   
cells treated with Aurora B kinase inhibitor ZM447439 (+ZM) for 45 minutes at 2µM concentration and cells 
treated with DMSO control (-ZM). Phospho-histone H3 (pH3) staining was used to indicate Aurora B 
inhibition. Insets indicate zoomed in images of lingering chromatin. Nuclei were stained with DAPI.  
 
As inhibition of MLCK is the primary downstream effect of Aurora B over-expression, I 
further analyzed if MLCK inhibition was the cause of non-enrichment of pMLC at the cleavage 
furrow. To test this possibility, I examined the localization of pMLC after induction of lingering 
chromatin in cells that were transiently transfected with a constitutively active or a kinase dead 
MLCK construct. In untreated cells, I consistently observed reduced enrichment of pMLC in 
anaphases with lingering chromatin (Figure 37). As per our prediction, cells treated with 
constitutively active MLCK showed enrichment of pMLC at the cleavage furrow even in the 
presence of lingering chromatin. 75% of cells transfected with a constitutively active MLCK 
demonstrated pMLC enrichment at the cleavage furrow compared to 20% of cells transfected 
with a kinase dead MLCK construct. These data indicate that MLCK inhibition is responsible for 
lingering chromatin induced MLC phosphorylation defects. Restoration of pMLC staining with 
Aurora B inhibition or MLCK activation suggest that these procedures restore rather than bypass 
pMLC inhibition pathway and support the hypothesis that deficient MLC phosphorylation 
caused by lingering chromatin at the cleavage furrow is due to increased Aurora B activation and 
resultant MLCK inhibition.  
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Figure 37. Phosphorylated MLC localizes to the cleavage furrow in the presence of lingering 
chromatin after activation of MLCK.  
Representative images in the top two panels demonstrate localization of pMLC at the cleavage 
furrow in the presence of lingering chromatin in untreated U2OS cells or cells transfected with a kinase dead 
MLCK construct. Representative images in the bottom two panels indicate pMLC localization at the cleavage 
furrow in the presence of lingering chromatin after transfection with a constitutively active MLCK construct. 
Insets indicate zoomed in images of lingering chromatin.  
3.2.9 Inactivation of the pMLC inhibition pathway causes DNA damage  
Cytokinesis progression in the presence of lingering chromatin results in DNA damage (Janssen 
et al., 2011). Therefore, cytokinesis inhibition caused by reduced MLC phosphorylation appears 
to be a protective mechanism, activated to avoid DNA damage that could be caused by cutting of 
the lingering chromatin by the ingressing cleavage furrow. If this were true, reversing pMLC 
inhibition should lead to an increase in the damage of lingering DNA. To test this hypothesis, I 
transfected U2OS cancer cells with a phosphomimetic MLC construct and examined the levels 
of phosphorylated γ-H2AX by immunoblotting, an indicator of DNA damage (Rogakou et al., 
1998). Compared to empty GFP control, transfection with a phosphomimetic MLC led to an 
increase in the levels of phosphorylated γ-H2AX, suggesting an increase in DNA damage. U2OS 
being a cancer cell line has higher frequency of lingering chromatin at the cleavage furrow. 
Therefore it appears that increased DNA damage after transfection of phosphomimetic MLC 
could be resulting from cleavage furrow cutting through the lingering chromatin. However, these 
results need to be verified in other cancer cell lines and also need to be compared with non-
cancer cells that typically do not have lingering chromatin at the cleavage furrow.  
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Figure 38. DNA damage is increased upon transfection of a phosphomimetic MLC construct in 
cancer cells U2OS.  
γ-H2AX protein levels were measured as an indicator of DNA damage after transfection of an empty 
GFP vector control or a phosphomimetic MLC (GFP-MLCDD) construct in cancer cells U2OS. γ-tubulin 
were used as loading controls.  
3.3 CONCLUSIONS AND DISCUSSION  
Results presented in the above two sections identify lingering chromatin as the most upstream 
event in the cytokinesis failure pathway that can now be further extended as follows:   
Lingering chromatin at the cleavage furrow → Aurora B over-expression → MLCK 
inhibition → deficient MLC phosphorylation → cytokinesis failure 
I have demonstrated that MLCK and phosphorylated MLC are inhibited in the presence 
of lingering chromatin and these deficiencies are the cause of lingering chromatin associated 
cytokinesis failure. Further, I have demonstrated that lingering chromatin and Aurora B over-
expression are not independent sources of MLCK inhibition but rather lingering chromatin 
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induces Aurora B over-expression to cause MLCK inhibition. I have provided the first evidence 
for lingering chromatin induced over-expression of Aurora B and have dissected the downstream 
pathway responsible for cytokinesis failure in the presence of lingering chromatin. 
Summarizing all the data presented in this dissertation, I would like to propose a model 
for the regulation of cytokinesis (Figure 39). At the onset of anaphase, when chromosomes begin 
to segregate away from the cleavage plane, MLCK becomes active leading to MLC 
phosphorylation, cleavage furrow ingression and cytokinesis completion. However in the 
presence of lingering chromatin such as anaphase bridges or lagging chromosomes, Aurora B is 
up-regulated to cause MLCK inhibition, deficient MLC phosphorylation and cytokinesis failure.  
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Figure 39. Proposed model for the regulation of cytokinesis.  
(A) During normal cytokinesis, MLCK phosphorylates MLC. Phosphorylated MLC (yellow stars) 
activates motor protein myosin II by promoting bipolar filament assembly and increasing its ATPase activity. 
The activated myosin then can interact with actin providing the contractile force necessary for the ingression 
of the cleavage furrow during cytokinesis. (B) Lingering chromatin at the cleavage furrow up-regulates 
Aurora B kinase (ArB). Up-regulated Aurora B kinase then leads to inhibition of MLCK, deficient 
phosphorylation of MLC and cytokinesis failure.  
Blue fill represents lingering chromatin. CF indicates cleavage furrow.  
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Role of Aurora B kinase in coordinating cytokinesis with chromatin clearance from the 
cleavage plane has been described before in the NoCut pathway (Norden et al., 2006; 
Steigemann et al., 2009). Being a component of the NoCut pathway, Aurora B delays abscission 
in the presence of chromatin bridges by stabilizing MKLP1 to anchor the intracellular canal 
between the dividing cells and inactivation of Aurora B leads to furrow regression.  The pathway 
described in our study identifies a similar function for Aurora B in regulating cytokinesis with 
chromatin clearance, but proposed to function at a different stage of cytokinesis. Our study 
identifies MLCK inhibition as the primary downstream effect of Aurora B activity in the 
presence of lingering chromatin and demonstrates that Aurora B over-expression is required for 
furrow regression. As MLCK and MLC phosphorylation are required for cleavage furrow 
ingression, which is an earlier stage of cytokinesis than abscission, it is possible that our pathway 
is different than the NoCut and acts early on to cause furrow regression before cytokinesis is 
progressed through abscission.  
The NoCut pathway described so far suggests that abscission is delayed until chromatin 
bridges are resolved. However, consequences of unresolved bridges are still unknown. 
Therefore, alternative possibility is that the delay in abscission in fact signals furrow regression 
and both MLCK inhibition and MKLP1 stabilization are a part of a single NoCut pathway. If this 
is true, it is possible that delay in abscission acts as a signal for MLCK inhibition and deficient 
MLC phosphorylation.  
In the yeast NoCut pathway, anillin-related proteins Boi1 and Boi2 localize at the site of 
the cleavage in an Aurora B-Ipl1 dependent manner to act as abscission inhibitors. Human anillin 
is also a known regulator of midbody formation, abscission and cleavage furrow ingression (Gai 
et al., 2011; Kechad et al., 2012; Piekny and Glotzer, 2008). Interestingly, anillin binds pMLC, 
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specifically phosphorylated by MLCK and this binding is required for maintenance of the furrow 
ingression (Straight et al., 2005). These data make anillin an attractive candidate that could 
potentially link the delay in abscission to furrow regression. Future work would be required to 
test this hypothesis. 
I have demonstrated that Aurora B protein levels are increased in the presence of 
lingering chromatin. However, the mechanism of this up-regulation is still not known. It is likely 
that lingering chromatin stabilizes Aurora B protein levels, a hypothesis that can be tested in the 
future. It was recently shown that ADA histone acetyltranferase is required for the activation of 
NoCut and forcing Aurora B on chromatin activates NoCut independent of midzone defects 
(Mendoza et al., 2009). I would like to test if a similar signaling mechanism is responsible for 
the up-regulation of Aurora B and the downstream inhibition of MLCK in the presence of 
lingering chromatin.  
3.3.1 Relevance of MLCK inhibition pathway in non-cancer cells  
At its inception, the main focus of this project was to identify the causes of cytokinesis failure in 
cancer cells. In doing so, I uncovered a pathway that appears to be an aberrancy of Aurora B 
over-expression phenotype of cancer cells. However, our results of lingering chromatin acting as 
an inducer of Aurora B over-expression and the observation of increased DNA damage after 
reversal of pMLC inhibition suggest that this pathway must be relevant during the regulation of 
normal cytokinesis as well. Even non-cancer cells experience chromosome segregation defects, 
albeit at lower frequency. In such rare cases, if the cleavage furrow cuts through the lingering 
chromatin, it can have disastrous consequences such as formation of grossly aneuploid progeny 
that might be unviable or could be tumorigenic if key tumor suppressors are inactivated by the 
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cutting of DNA. Therefore it is crucial to prevent DNA damage caused by the ingressing 
cleavage furrow by making it regress. It might be more beneficial to form a tetraploid cell that 
can be eliminated in a p53 dependent manner rather than forming a grossly aneuploid or unviable 
progeny. This idea can be supported by the fact that p53 loss often precedes an appearance of 
tetraploid cells during early stages of tumorigenesis and only tetraploids that are null for p53 
posses the ability to form tumors in mice.  
                  Cancer cells mis-segregate chromosomes at a much higher frequency causing an 
increase in Aurora B protein levels, probably without any changes in its gene copy number. 
Incidental loss of p53 along with increased Aurora B levels can then lead to illicit survival of the 
resultant tetraploid progeny making this pathway an aberrancy of tumor tissues. 
I would further like to suggest that MLCK inhibition by Aurora B kinase is required even 
at earlier stages of cytokinesis. In early mitosis, Aurora B is chromatin associated but later 
dissociates from chromatin during cytokinesis (Kelly et al., 2007; Vader et al., 2006). Similarly, 
MLCK activity is inhibited in early mitosis but increases during anaphase. This raises the 
possibility that chromatin associated Aurora B might inhibit MLCK in early mitosis to avoid 
premature ingression of the cleavage furrow when chromosomes are still at the metaphase plate. 
These ideas are still at a speculative stage and further work is required to validate them 
experimentally.  
Even in 21st century, cancer is a major cause of morbidity and mortality in human 
population (Siegel et al., 2012). Basic research in cancer biology is at the frontier of our war on 
cancer. By dissecting the cytokinesis failure pathway in cancer cells, we have contributed our 
small share in understanding the genomic destabilizing events of tumor development as well as 
have gained insights in the regulation of the cytokinesis in non-cancer cells. This research 
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improves our understanding of the pathology of the disease and may also open avenues for new 
therapeutic approaches.  
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4.0  MATERIALS AND METHODS 
4.1 CELL CULTURE 
Table 1 shows a list of non-cancer and cancer cell lines used in this study. The cells were 
propagated in the growth medium recommended by the manufacturer. Oral cancer cells lines 
UPCI:SCC103 and UPCI:SCC70 were kindly provided by Dr Susanne Gollin (University of 
Pittsburgh). HFF-hTERT cell lines were kindly provided by Dr. Edward Prochownik (University 
of Pittsburgh). 
 
  
Table 1. List of cell lined used in this study 
Non-cancer cell lines Abbreviation Tissue of origin Growth medium 
Retinal pigment epithelial 
cells immortalized with 
human telomerase reverse 
transcriptase or hTERT 
RPE1 Retina 
DMEM-F12 + 10% 
FBS 
Primary fibroblasts Fibroblasts Skin DMEM + 10% FBS 
Oral keratinocytes 
immortalized with hTERT 
OKF-hTERT Oral mucosa 
Defined keratinocyte 
medium 
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Human foreskin fibroblasts 
immortalized with hTERT 
HFF-hTERT Foreskin 
DMEM + 10% FBS 
+1% Penicillin-
streptomycin + 1% L-
glutamine 
Cancer cell lines Abbreviation Tissue of origin Growth medium 
Oral squamous cell 
carcinoma 
UPCI:SCC103 Tongue 
MEM + 10% FBS + 
1% non-essential 
amino acids + 1% L - 
glutamine 
Oral squamous cell 
carcinoma 
UPCI:SCC70 
Retromolar 
trigone or RMT 
MEM + 10% FBS + 
1% non-essential 
amino acids + 1% L-
glutamine 
Osteosarcoma U2OS Bone 
McCoys 5A medium 
+ 10% FBS 
Lung carcinoma A549 Lung 
F-12K or MEM +10% 
FBS+1% non-
essential amino acids 
1% L-glutamine 
Cervical adenocarcinoma HeLa Cervix DMEM + 10% FBS 
Liver adenocarcinoma SK-HEP1 Liver 
MEM+10% FBS +1% 
non-essential amino 
acids+1% l-glutamine 
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Colorectal carcinoma HCT116 Colon 
McCoys 5a medium+ 
10% FBS 
 
4.2 MLCK IMMUNOPRECIPITATION  
Cells were lysed using modified radioimmunoprecipitation (RIPA) buffer (50mM Tris-HCL 
pH7.4, NaCl 150mM, NP-40%) with freshly added protease inhibitors (1mM PMSF, 100mM 
leupeptin and pepstatin each) and phosphatase inhibitors (100mM NaF and 1mM Na3VO4). 
Lysates were clarified by centrifugation at 10,000g for 15 minutes. Supernatants were incubated 
with MLCK antibody (Sigma Aldrich) at 40C for 2 hours. A slurry of Protein A sepharose beads 
(Amersham Biosciences) was added to the reaction and the reaction was further incubated at 40C 
for 2 hours. Immunoprecipitates were washed with RIPA buffer three times and were divided 
into two halves. One half was subjected to electrophoresis and immunoblotting to confirm 
MLCK immunoprecipitation and the other half was subjected to an in vitro kinase assay to 
measure MLCK activity. Immunoblots were also quantified using Image J program and the 
kinase assay values were given minor adjustments (<10%) by multiplying the substrate 
phosphorylation data with the ratio of the intensities of the scanned immunoblots.  
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4.3 IN VITRO KINASE ASSAY 
MLCK activity was determined using an in vitro kinase assay, performed as described previously 
(Poperechnaya et al., 2000). Half of the immunoprecipitates were incubated with a reaction 
mixture containing 10mM MOPS pH 7.0, 1mM DTT, 4mM MgCl2, 0.1mM CaCl2, 1µM 
calmodulin (Sigma Aldrich), 0.1mM [γ 32P] ATP (Perkin-Elmer) and 15µM MLCK substrate 
(Biomol). The reaction was kept agitated using a low speed vortexer. At the indicated time points 
10µl of the reaction supernatant was spotted onto P81 phosphocellulose squares (Millipore). 
Squares were washed 10 times each using 2mls of 75mM phosphoric acid. Transfer of radio- 
labeled ATP to the substrate was measured using scintillation counter.  
4.3.1 MLCK activity assay in the presence of purified Aurora B kinase and Aurora C 
kinase 
To study the effect of Aurora B on MLCK activity, assay was performed in the presence of 
purified Aurora B kinase (Upstate Cell Signaling Solutions) at the concentration of 1µg/100µl of 
reaction buffer (500mM Tris-HCL, pH 7.5, 1.0mM EGTA, 150mM DTT and 1X Magnesium 
ATP cocktail (Upstate cell signaling solutions).  
To study the effect of Aurora C on MLCK activity, the assay was performed in the 
presence of purified Aurora C kinase (Cell signaling solutions) at the concentration of 1 
µg/100µl of reaction buffer containing 25mM Tris-HCl pH 7.5, 10mM MgCl2, 5mM β-
glycerophosphate, 0.1mM Na3VO4 and 2mM DTT.  
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4.4 IMMUNOBLOTTING  
Cells were lysed using RIPA buffer or hot SDS buffer. Protein concentration was measured by 
Lowry assay (Bio-Rad). Lysates were subjected to SDS - polyacrylamide gel electrophoresis and 
were transferred to a PVDF or a nitrocellulose membrane. Membranes were blocked with 5% 
milk in TBSN and were probed with the primary antibodies diluted in 5% milk in TBSN. After 
overnight incubation with primary antibody, membranes were incubated with HRP-conjugated 
secondary antibodies (1:5000, GE healthcare). Proteins were detected using chemiluminescent 
substrate (Thermo Fisher) and M35 A X-OMAT Processor (Kodak). Primary antibodies and the 
required concentrations are given in Table 2. 
4.4.1 Urea/glycerol gel electrophoresis 
Unphosphorylated and phosphorylated forms of MLC were detected by urea/glycerol gel 
electrophoresis and immunoblotting as described previously (Word et al., 1991). Cells plated in 6 
well plates were harvested using ice cold TCA containing 10mM DTT.  After centrifugation, cell 
pellets were washed three times with diethyl ether and were resuspended in urea sample buffer 
containing 8M urea, 20mM Tris-HCl, 23mM glycine, 10% glycerol, 10mM EGTA, and 0.2% 
bromophenol blue, pH 8.6. Lysates were subjected to electrophoresis, were transferred onto 
PVDF membrane, and were probed with anti-MLC antibody (A kind gift from Dr. James Stull, 
University of Texas Southwestern Medical Centre).   
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4.5 IMMUNOFLUORESCENCE MICROSCOPY  
Cells were seeded on sterile 22X22 mm coverslips placed in 35mm tissue culture dishes. 
Immunofluorescence staining for MLCK was performed as described previously using gradient 
methanol fixation (Dudnakova et al., 2006). Cells were fixed with 100% ice cold methanol at  
-200C for 10 minutes followed by fixation with 75%, 50% and 25% methanol at 40C for 3 
minutes each. For the immunofluorescence staining of pMLC, Aurora B kinase and pH3, cells 
were fixed with 4% paraformaldehyde (Sigma-Aldrich) in PBS for 20 minutes and cell 
membranes were permeabilized using 0.1% Triton (Fisher) for 5 minutes.  
Cells were blocked with 1% BSA in PBS for 1 hour and were stained with the indicated 
primary antibodies for 1 hour at the concentration given in Table 2. Alexa Fluor 488 or Alexa 
Fluor 568 conjugated secondary antibodies (Invitrogen) were used at 1:250 dilutions for 1 hour. 
Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) at 1µg/ml concentration for 5 
minutes. Actin was stained using rhodamine-conjugated phalloidin (Cytoskeleton). Cells were 
visualized using an Olympus BX60 epifluorescence microscope and images were captured using 
Hamamatsu Argus-20 CCD digital camera. 
 
Table 2. List of antibodies used in this study 
Primary Antibody Manufacturer 
Dilution for 
immunobloting 
Dilution for 
immunofluorescence 
microscopy 
MLCK Sigma 1:5000 1:500 
Aurora B kinase BD transduction 1:500 1:150 
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Aurora A kinase BD transduction 1:500 NA 
Aurora C kinase Abcam 1:500 NA 
MLC phosphorylated on 
Ser19 
Cell Signaling 
Technology 
1:500 1:200 
Actin Cytoskeleton 1:3000 1:200 
γ-Tubulin Sigma 1:5000 NA 
Phosph-histone H3 Millipore 1:5000 1:1000 
Phospho-γ-H2A.X 
Cell Signaling 
Technology 
1:5000  
4.6 TRANSFECTIONS 
4.6.1 Recombinant DNA 
Phosphomimetic MLC construct was kindly provided by Dr. Kathleen Kelly (National Cancer 
Institute, Bethesda) (Ward et al., 2002). As described in this paper, pEGFP-MLC construct was 
made using T7-7-MLC. Site-directed mutagenesis (Stratagene) was performed using pEGFP-
MLC as a template to generate pEGFP-MLC (18D, 19D) mutant. Constitutively active and 
kinase dead MLCK constructs were kindly provided by Dr. Raj Wadgaonkar (SUNY downstate 
medical center) (Wadgaonkar et al., 2003). As described in this paper, constitutively active 
MLCK lacks C-terminus amino acid 1745- 1914. Endothelial MLCK was used as a template to 
obtain the deleted inserts by PCR analysis. PCR product was cloned into TOPO expression 
vector (Invitrogen) in frame with V5 and His tags. Kinase dead MLCK construct lacks the ATP 
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binding site consisting of amino acids 1580-1607. To generate kinase dead construct, PCR 
product of amino acids 1-1580 was cloned into TOPO expression vector followed by the addition 
of C-terminal portion. Both the constructs are expressed under CMV promoter.  
4.6.2 DNA transfection  
Cells were seeded on 22X22 mm sterile coverslips. After 6-8 hours, cells were transfected with 
1µg of the indicated DNA using transfection reagent FuGENE6 (Roche diagnostics) as per 
manufacturer’s guidelines. Following transfection, cells were grown in starvation medium OPTI-
MEM for 24 hours followed by growth in full medium for 12 hours. Cells transfected with 
phosphomimetic MLC were used for further analysis 36 hours after transfection. For 
constitutively active and kinase dead MLCK constructs, the transfection procedure was repeated 
after 36 hours and cells were used for further analysis after 72 hours of total transfection.  
4.6.3 RNA transfection  
Aurora B knock-down was performed using two different siRNAs. siRNA # 1 targets the N-
terminal region of the Aurora B mRNA and was commercially available form Qiagen 
(Hs_AURKB_5, catalog number  S102622032). siRNA # 2 was designed as published 
previously (Klein et al., 2006) using the sequence 5’ GGAAAGAAGGGAUCCCUAA 3’ 
(Dharmacon) that targets the C-terminal region of the mRNA. Cells were transfected using a 
reverse transfection protocol using transfection reagent HiPerFect as per manufacturer’s 
guidelines. To achieve complete knock-down of Aurora B, siRNAs were used at 167 nanomolar 
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concentration for 48 hours or 24 hours. To achieve partial knock-down of Aurora B, siRNAs 
were used at 50 nanomolar concentration for 24 hours.  
4.7 CELL CYCLE SYNCHRONIZATION  
4.7.1 S-phase arrest 
Cells were arrested in S phase with a double thymidine block. Cells were treated with thymidine 
(5mM for non-cancer cells and 2mM for cancer cells) for 18 hours. They were released in the 
fresh medium for 8 hours followed by second treatment with thymidine for 18 hours.  
4.7.2 Mitotic arrest  
To compare MLCK activity and expression, cells were arrested in mitosis with 18 hours of 
nocodazole treatment at the concentration of 400 ng/ml for RPE1 and 300 ng/ml for 
UPCI:SCC103 cells. To achieve comparable mitotic indices for Aurora B expression analysis, it 
was necessary to treat cells with nocodazole as follows: OKF-hTERT- 600 ng/ml, HFF-hTERT – 
500 ng/ml both treated for 24 hours.  RPE1- 400 ng/ml, A549 and U2OS – 300 ng/ml and 
UPCI:SCC103 – 25 ng/ml, each treated for 18 hours.  
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4.8 IRRADIATION AND UV- C TREATMENT  
After plating the cells for 18-24 hours, they were exposed to 2.8-3 Gy of γ-radiation using 137Cs 
as a source. Cells were used for further analysis after allowing them to recover for 24 hours. 
Cells were exposed to 10J of UV-C using UV-C lamp model X-15 (Spectroline) and were used 
for further analysis 24 hours later. 
4.9 DRUG TREATMENTS 
Aurora B kinase was inhibited using Aurora B inhibitor ZM447439 (Tocris) at 2 µM 
concentration for 45 minutes. 
To induce lagging chromatin, cells were treated with Eg5 inhibitor monastrol (Tocris) at 
100 µM concentration for 16 hours. Cells were allowed to proceed through anaphase by 
releasing them from the block for 2 hours.  
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